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1. Introduction 
1.1. Neuroblastoma 
  Neuroblastoma (NB) is an aggressive childhood malignancy that accounts for 8-10% 
of all childhood cancers [1] and approximately 15% of all pediatric oncology deaths [2]. It is 
a solid, extracranial tumor that originates from neural crest cells of the sympathetic nervous 
system and consists of undifferentiated, neuroectodermal cells. In general, NB tumors can 
be located at any side along the sympathetic chain, such as neck, chest or pelvis, but the 
most common location of primary tumor growth is abdominal, generally within the adrenal 
glands [3]. The clinical appearance of NB is heterogeneous, as patients may experience 
spontaneous regression or differentiation while others endure aggressive growth and rapid 
spread of the disease. To account for this wide variability in clinical behavior, staging 
systems have been established to assign patients to different risk groups with the purpose 
of avoiding overtreatment among low-risk patients while intensifying therapy for patients 
identified as high-risk. The International Neuroblastoma Staging System (INSS) assigns 
patients to different groups, based on their age at time of diagnosis, extent of the disease 
and the resectability of the tumor [4, 5]. Since this staging system is based on a post-
surgical evaluation, the International Neuroblastoma Research Group (INRG) established a 
new pre-treatment risk stratification system (INRGSS) to improve reproducibility of clinical 
trial results. This INRG staging system is based on image-defined risk factors (IDRF), age 
and biological prognostic factors, such as MYCN-amplification, chromosomal 11q 
aberrations or DNA ploidy [6]. About 20% of NB patients exhibit an amplification of the 
oncogene MYCN, which is associated with rapid progression of the disease and poor 
prognosis [7, 8]. Deletion of chromosome 11q is associated with decreased event-free 
survival [9]. DNA ploidy can be used as a prognostic factor for infants with NB, for which 
diploidy of tumor cells was shown to be associated with advanced tumor stages and 
reduced responsiveness to chemotherapy [10, 11]. In summary, about 50% of all NB cases 
belong to the high-risk group [2], characterized by poor prognosis and a 5 year event-free 
survival rate of less than 50% despite intensive multimodal therapy [12]. 
1.2. Treatment of neuroblastoma 
  Since clinical behavior of NB is very heterogeneous, treatment of NB varies widely 
depending on the risk group to which patients are initially assigned. The treatment of low-
risk NB includes observation only (generally in the special case of INSS stage 4S) or 
moderate chemotherapy. In case of intermediate-risk patients, treatment is based on 
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surgical removal of the tumor, followed by moderate multi-agent chemotherapy [5]. The 
treatment of high-risk patients is the most challenging and can be divided into induction 
therapy, consolidation therapy and maintenance therapy. Induction therapy aims at 
reducing the tumor burden and is based on high dose multi-agent chemotherapy as well as 
irradiation of the primary tumor site. Consolidation therapy includes removal of the primary 
tumor and metastases. Further high-dose myeloablative chemotherapy, followed by rescue 
with autologous hematopoietic progenitor cells is currently used as consolidation therapy in 
most of the high-risk clinical trials [5, 13-15]. Although the majority of high-risk patients 
initially respond to induction and consolidation therapy, they often develop progressive 
disease or relapse. These relapses are potentially caused by minimal residual disease 
(MRD) consisting of cells that have acquired drug resistance or that have been otherwise 
selected from a heterogeneous population of tumor cells during induction and consolidation 
therapy [12, 16]. Therefore, maintenance therapy aims at eradication of minimal residual 
disease that could potentially cause a relapse. The standard treatment of minimal residual 
disease is based on the application of 13-cis-retinoic acid (Isotretinoin) [17, 18]. Retinoic 
compounds are natural or synthetic derivates of vitamin A that are able to induce cell 
growth arrest or differentiation in NB cells [19]. Furthermore, the synthetic vitamin A 
derivate Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) is under investigation for 
application in NB treatment [20, 21]. Fenretinide was demonstrated to be effective against 
NB cell lines, even if these cells were resistant to other retinoic compounds such as 13-cis-
RA [22]. Mechanisms suggested to be involved in 4-HPR-mediated cytotoxicity include the 
intracellular accumulation of ceramides and production of reactive oxygen species (ROS) 
[23, 24]. 
  Despite existing intensive multi-modal standard therapy, the outcome of high-risk NB 
patients remains poor, emphasizing the need for new and more effective approaches to 
treat minimal residual disease. Therefore, immunotherapeutic approaches are under 
current investigation and appear to be promising alternatives to address this critical 
problem.   
1.3. Immunotherapy of neuroblastoma 
  Cancer immunotherapy aims at activating the immune system to specifically target 
and kill tumor cells. A variety of immunotherapeutic strategies is currently being 
investigated that can be divided into two broad categories. Passive immunotherapeutic 
approaches mediate an immediate but only transient effect. They are based on the direct 
application of immunostimulatory cytokines, such as interleukin-2 (IL-2) or monoclonal 
antibodies (mAbs), which specifically target a tumor-associated antigen (TAA). Additionally, 
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immune effector cells such as T cells or NK cells can be adoptively transferred for passive 
immunotherapy. In contrast, active immunotherapeutic strategies are utilized to induce a 
long-lasting anti-tumor effect by stimulating the immune system with the help of cancer 
vaccines. These cancer vaccines include peptide/protein vaccines, DNA vaccines or 
dendritic cell vaccines.  
  The susceptibility of a certain tumor entity to immunotherapy in general, as well as 
the selection of the most promising immunotherapeutic approach, depends on the 
immunogenicity of the tumor. An important prerequisite for immunogenicity is the 
expression and successful presentation of TAAs to induce a specific immune response. In 
case of NB, several TAAs have already been identified (Table 1.3) [25] confirming that NB 
can be recognized by the immune system.  
 
Table 1.3.: Tumor-associated antigens expressed in human neuroblastoma tumors,  
adapted from Gray et al. [25]. 
Antigen Nature of antigen Tumor expression Normal tissue expression 
 
MYC-N 
 
Transcription factor 
and proto-oncogen 
 
Over-expression in >40% 
of patients with metastatic 
disease 
 
Little expression beyond 
foetal development  
 
Disialoganglioside 
(GD2) 
 
Glycolipid 
 
100% of NB 
 
CNS neurons and peripheral 
pain fibers 
 
Tyrosine 
hydroxylase 
 
Catecholamine 
biosynthesis 
 
100% of NB samples 
 
Adrenal medulla and CNS 
dopaminergic neurons 
 
Hu antigens 
 
Neuronal-specific 
RNA binding proteins 
 
80% of NB express HuD 
 
Central and peripheral 
nervous tissue 
 
Survivin 
 
Inhibitor of apoptosis 
 
Expression 26/26 high-
risk NB 
 
Low or absent in normal 
tissue 
 
Melanoma 
antigen A 
(MAGE) family 
 
Cancer germline 
antigens 
 
8/10 NB express at least 
1 MAGE family antigen 
 
Little expression in normal 
tissue other than testis  
 
NY-ESO-1 
 
Cancer germline 
antigen 
 
18/22 (82%) NB samples 
 
Normal tissue expression 
restricted to testis 
 
PReferentially 
expressed 
Antigen in 
MElanoma 
(PRAME) 
 
Cancer germline 
antigen 
 
87/94 (93%) NB samples 
 
Expression in normal tissue 
restricted to testis 
 
Anaplastic 
lymphoma kinase 
(ALK) 
 
 
Receptor tyrosine 
kinase 
 
Expression in 14/16 NB 
samples 
 
Limited expression on neural 
tissue 
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Despite the expression of these TAAs, spontaneous immune responses in NB patients are 
generally weak and fail to effectively control tumor growth on their own [25]. Various factors 
have an impact on the induction of an effective anti-tumor response, such as the nature of 
the antigen or the development of immune escape mechanisms by the tumor. Furthermore, 
low expression of the antigen might not be sufficient to effectively induce a specific immune 
response. In the case of NB, the disialoganglioside GD2 is highly expressed on NB tumors. 
Gangliosides are sialic acid-containing glycosphingolipids. They consist of a hydrophobic 
ceramide, which is anchored in the cell membrane, and an extracellular hydrophilic 
oligosaccharide chain, which is connected to one ore more molecules of sialic acid [26]. 
GD2 is consistently expressed on neuroectodermal tumors, such as NB and most 
melanomas. Further, GD2 has been reported to be expressed on a variety of other tumor 
entities, such as bone and soft-tissue sarcomas, small cell lung cancer or brain tumors [27, 
28]. Physiological expression of GD2 is restricted to the neurons, skin melanocytes and 
peripheral pain fibers [29]. So far, the exact function of GD2 is not completely understood, 
but it could be shown that GD2 together with GD3 is involved in the attachment of tumor 
cells to extracellular matrix proteins [30].  
  Due to its high expression in NB but restricted physiological expression, GD2 is a 
suitable TAA for immunotherapeutic approaches in NB treatment. Importantly, analysis of 
tumor samples derived from patients before and after treatment with anti-GD2 antibodies 
revealed that GD2 expression persisted in refractory or recurrent NB, indicating that GD2 is 
not modulated off the cell membrane during therapy [31]. This stable expression of GD2 on 
NB tumors is an important prerequisite for GD2-directed immunotherapies. As a glycolipid, 
GD2 is a T cell-independent antigen and cannot induce a GD2-specific T cell response. 
Therefore, GD2-directed therapeutic appoaches focus on passive immunotherapy with 
GD2-specific antibodies.  
 
  In addition to the nature of the TAA and level of its expression, the presentation of 
antigens in the context of MHC class I molecules is another factor that has an impact on 
the immunogenicity of a tumor. Antigen presentation can be negatively affected in several 
ways. This can be caused by defects in the antigen processing machinery as well as low or 
absent MHC class I expression. In case of NB, it is known that tumors exhibit low or absent 
MHC class I expression, thereby being unable to present TAAs to cytotoxic T cells [32]. 
The expression of antigen processing genes, another prerequisite for a successful 
presentation of the TAAs, is only low in NB [33, 34]. Although low or absent MHC class I 
expression negatively affects activation of cytotoxic T cells, this actually renders NB cells 
sensitive to recognition by NK cells. In general, NK cell-mediated lysis of tumor cells is 
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further promoted by expression of activating NK cell ligands on tumor cells, such as 
MICA/B, ULBP-1 or ligands for NCRs, which will be discussed in more detail in 1.4. In the 
case of NB, NCRs and the DNAX accessory molecule-1 (DNAM-1) have been shown to 
play an important role in NK cell-mediated lysis [35, 36]. Unfortunately, tumor cells have 
evolved mechanisms to escape recognition by NK cells. This includes either 
downregulation or release/shedding of activating NK cell ligands from the tumor cell 
surface. Further, the release of soluble activating ligands can result in downregulation of 
activating receptors, such as NKG2D, on effector cells [37-39]. Immunosuppressive 
cytokines, such as transforming growth factor-β (TGF-β), produced in the tumor 
microenvironment also negatively affect the expression of activating receptors as well as 
some of their ligands [40-42].  
  Based on the current knowledge about the immunogenicity of NB, various novel 
passive and active immunotherapeutic approaches specifically targeting NB are being 
evaluated. Active anti-NB strategies include dendritic cell (DC) vaccines, DNA vaccines 
and peptide/protein vaccines. DC vaccines are generated by pulsing autologous dendritic 
cells with tumor antigen, which can be either provided as peptides, tumor lysates or tumor 
cell RNA.   
  Although NB-specific DC vaccines have been shown to mediate tumor immunity in a 
NB mouse model, their application in two small phase I clinical trials failed to induce a 
significant anti-tumor response [43, 44]. NB-specific DNA vaccination approaches focus on 
survivin [45], tyrosin hydroxylase [46, 47] or MYCN [48] as TAA. Further, DNA vaccines 
based on GD2 peptide mimotopes are under investigation [49]. These NB-targeting DNA 
vaccines have been shown to be safe and effective in the induction of antigen-specific T 
cells, thereby mediating an anti-tumor effect in pre-clinical experiments. Despite these 
promising pre-clinical results, none of these DNA vaccines has entered a clinical trial so 
far.  
  Additionally, protein vaccines based on the application of anti-idiotype antibodies 
(anti-IdAbs) are under investigation. These anti-IdAbs consist of paratopes that mimic the 
nominal antigen GD2 and thereby induce the induction of anti-anti-IdAbs, which in turn 
recognize the nominal antigen on tumor cells. Recently, the generation and 
characterization of the new anti-IdAb ganglidiomab has been reported [50]. Anti-idiotype 
properties of ganglidiomab were confirmed in vitro and vaccination with ganglidiomab 
resulted in a GD2-specific anti-NB immune response in a syngeneic NB mouse model. The 
anti-IdAb 1A7 has been already applied as a GD2 surrogate in a clinical trial with high-risk 
NB patients [51]. This study revealed the generation of anti-mAb1A7 antibodies in all 31 
vaccinated patients and further reported CDC (complement-dependent cytotoxicity) and 
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ADCC (antibody-dependent cellular cytotoxicity) activity in sera of patients. There were no 
systemic toxicities and only local reactions to subcutaneous 1A7 application were recorded 
as adverse events. Vaccination of melanoma patients with the GD2-mimicking anti-IdAb 
TriGem resulted in a GD2-specific immune response in 40 out of 47 patients [52]. In 
addition to anti-IdAbs, GD2 peptide mimotopes offer another approach to active 
immunotherapy in the form of a peptide/protein vaccine. Translation of the weakly 
immunogenic glycolipid structure of GD2 into the protein structure of GD2 peptide 
mimotopes provides an important baseline for the induction of a GD2-specific immune 
response. The application of GD2 peptide mimotopes in a syngeneic mouse model 
resulted in significantly reduced tumor growth [53]. 
  Although the induction of a long lasting anti-NB immune response by active 
immunization would be desirable, the immunosuppressed condition of most NB patients 
after intensive initial therapy remains a major obstacle. Therefore, the most advanced 
immunotherapeutic anti-NB approaches at the moment are passive immunotherapeutic 
strategies based on the application of GD2-specific antibodies. The disialoganglioside GD2 
is highly expressed on NB cells while physiological expression is restricted, resulting in 
moderate but manageable side effects of GD2-targeted immunotherapy. Over the last 
decades, a variety of monoclonal GD2-specific antibodies have been generated and 
entered clinical trial evaluation. The first antibodies employed in clinical trials were the 
murine antibodies 3F8 [28, 54, 55] and 14G2a [56-58], which revealed limited tumor 
responses in some patients, mainly in a minimal residual disease setting, accompanied by 
generation of human-anti-mouse antibodies (HAMA). Due to their murine nature, 3F8 and 
14G2a are immunogenic and thereby induce the generation of those HAMA, resulting in 
limited anti-tumor activity of the therapeutic murine antibodies. Interestingly, it was shown 
for some patients that low levels of HAMA antibodies correlated with improved survival 
[59]. A possible explanation might be provided by the idiotype network theory of Jerne [60]. 
According to this network theory, some of the generated HAMA antibodies might have anti-
idiotype characteristics and specifically bind the paratopes of anti-GD2-antibodies. Hence, 
these anti-IdAbs mimic the nominal TAA GD2 and can induce GD2-specific antibodies 
(anti-anti-IdAbs).  
  Since ADCC in addition to CDC is known to be one of the main mechanisms by which 
antibodies mediate their anti-tumor effect [61, 62], therapeutic protocols have been 
adapted to include cytokines, such as IL-2 [63, 64] and granulocyte-macrophage colony-
stimulating factor GM-CSF [65] that increase the number of lymphocytes as well as their 
capacity to mediate ADCC [66, 67]. 
Introduction 
 
7 
 
  To reduce the immunogenicity of murine anti-GD2 antibodies, the human/mouse 
chimeric antibody ch14.18 was generated. This antibody consists of the murine variable 
regions of 14G2a and human IgG1 constant regions [68]. GD2-binding properties of 
ch14.18 and 14G2a are comparable and ch14.18 was reported to be even more effective 
in mediating ADCC towards NB cells [69, 70]. Ch14.18 has been used in several clinical 
trials, either as a single agent or in combination with cytokines [71-73]. The most promising 
results of therapeutic application of ch14.18 have been recently shown in a clinical phase 
III trial conducted by the Childen`s Oncology Group in the US. There, a treatment protocol 
based on a combination of ch14.18, GM-CSF, IL-2 and 13-cis-retinoic acid resulted in a 
significant increase of the 2-year event-free survival rate from 46% to 66%. (Fig. 1.3) [74]. 
The most common side effects of this treatment were pain, hypotension, capillary leak 
syndrome, fever and hypersensitivity reactions. Pain is thought to be caused by binding of 
the administered antibody to GD2 on peripheral nerve fibers and subsequent activation of 
the complement system [75, 76]. The capillary leak syndrome is attributed to systemic IL-2 
application [77].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Event-free survival of high-risk NB patients [74, modified]. Kaplan-Meier plot for event-free 
survival of patients either treated with immunotherapy, based on a combination of ch14.18, GM-CSF, IL-2 and 
13-cis-retinoic acid or standard therapy. Two year event-free survival rate ± SE is shown for each treatment 
group. 
 
  Since the chimeric antibody ch14.18 still contains murine regions, which can induce 
the generation of human-anti-chimeric antibodies (HACA), ch14.18 was humanized to 
further decrease immunogenicity of this anti-GD2 antibody. The humanized antibody 
hu14.18 is 98% human and contains only the complementarity-determining regions of the 
original murine antibody. To further increase the potential of GD2-specific antibodies and 
reduce side effects of a systemic cytokine application, immunocytokines (IC) such as 
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hu14.18-IL-2 are under current investigation. Immunocytokines were generated to combine 
the specificity and effector functions of an antibody with the immune stimulating potential of 
a cytokine, resulting in targeted delivery of the cytokine to the tumor microenvironment. 
Hu14.18-IL-2 is a fusion protein of the humanized GD2-specific antibody hu14.18 and IL-2 
and has already entered clinical trials [78, 79]. These GD2-directed passive 
immunotherapeutic approaches demonstrated clinical activity and safety to exploit GD2 as 
TAA in neuroblastoma. This provides an important baseline for further improvement of 
GD2-directed therapeutic regimens. Along this line, this thesis evaluates a new GD2-
directed immunotherapy, based on effector NK cells specifically directed towards GD2 by 
expression of a chimeric antigen receptor.   
1.4. Natural killer cells 
  Natural killer cells (NK cells) are cells of the innate immune system that mediate lysis 
of virus-infected or malignant transformed cells and produce immunoregulatory cytokines 
(IFN-γ, TNF-α and GM-CSF). They are characterized as large granular lymphocytes that 
lack expression of CD3 [80, 81]. In humans, NK cells can be divided into two subsets with 
distinct effector functions, according to their CD56 and CD16 expression. The majority of 
NK cells (90%) characteristically exhibit only low expression of CD56 but high expression 
of CD16 (CD56dim CD16bright), therefore having a cytotoxic phenotype capable of mediating 
ADCC. In contrast, 10% of all NK cells exhibit high expression of CD56 and low or absent 
expression of CD16 (CD56bright CD16dim). These cells are less cytotoxic but produce 
immunoregulatory cytokines [82]. In contrast to T cells, NK cells are able to mediate 
cytotoxicity to target cells without prior sensitization [80, 83]. 
  The complex process of NK cell activation is tightly regulated and based on the 
interaction of activating or inhibitory receptors, expressed on NK cells, with their respective 
ligands expressed on target cells. NK cell receptors are germ-line encoded and hence do 
not have to undergo somatic recombination [84, 85]. Lysis of healthy autologous cells is 
prevented by signaling through inhibitory receptors, such as KIR (killer cell 
immunoglobulin-like receptors) or the CD94/NKG2A receptor. Inhibitory KIRs, in contrast to 
activating KIRs, characteristically express a long cytoplasmic tail including a tyrosine-based 
inhibitory motif (ITIM), which is also a feature of the inhibitory CD94/NKG2A heterodimer. 
Inhibitory signaling by KIR and CD94/NKG2A is induced upon engagement of these 
receptors with allelic variants of HLA class I molecules and HLA-E molecules, respectively 
[86-88]. Lysis of healthy autologous cells in the absence of activating signaling is thereby 
prevented. In contrast, decreased or even absent HLA class I expression, which can be 
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caused by viral infection or malignant transformation, renders cells susceptible to NK cell-
mediated lysis (missing self hypothesis) [84, 89].  
  In addition to these inhibitory receptors, NK cells express a variety of activating 
receptors. The activating receptor CD16 (FcγRIIIa) is a low affinity receptor for IgG that 
enables NK cells to mediate ADCC by binding to IgG that specifically recognizes and binds 
a certain antigen on target cells [90, 91]. Further, activating signaling can be mediated by 
natural cytotoxicity receptors (NCR), such as NKp46 (NCR1), NKp44 (NCR2) and NKp30 
(NCR3) that belong to the Ig-like superfamily. NKp46 and NKp30 are expressed on both 
resting as well as activated NK cells, in contrast to NKp44, which is only present on 
activated NK cells [92-94]. Although NCRs have been shown to be involved in NK cell-
mediated lysis of different tumor entities, such as NB or leukemia [35, 95], little is known 
about cellular ligands for NCR.  B7-H6 and the HLA-B-associated transcript 3 (BAT3) are 
known NCR ligands expressed on tumor cells that can mediate NK cell activation through 
engagement with NKp30 [96, 97]. Additionally, NCRs have been shown to recognize viral 
components [98-100]. The C-type lectin-like receptor NKG2D is another activating NK cell 
receptor, which recognizes ligands that are structurally related to MHC class I. This group 
consists of the MHC class I-related chain (MIC) A and B (MICA and MICB) as well as the 
unique long 16-binding proteins 1-4 (ULBP1, ULBP2, ULBP3, ULBP4) [101-104]. 
Expression of these ligands is induced or upregulated on cells upon stress, infection or 
malignant transformation and has been shown to play a role in cytotoxic activity of NK cells 
towards melanoma, NB and leukemia cell lines [105]. Activating ligands Nectin-2 (CD112) 
and the poliovirus receptor (PVR, CD155), which are physiologically expressed on 
epithelial and endothelial cells and overexpressed on certain tumor entities, can be 
recognized by Ig-like superfamily member DNAM-1 (dynax-accessory-molecule-1, CD226) 
[106, 107]. Interaction of DNAM-1 with its ligands has been shown to be involved in NK 
cell-mediated killing of tumor cells [36, 108, 109]. 
  Due to the wide variety of NK cell receptors expressed, NK cell activation is a very 
complex process and so far its regulation is not completely understood. It is known though 
that recognition of IgG by CD16 is sufficient to induce activation by itself, in contrast to 
other activating receptors, which supposedly have to synergize with each other to induce 
activation of NK cells [85].  
  In general, NK cells are capable of inducing apoptosis in target cells by one of two 
pathways. In the case of predominantly activating signaling, via engagement of activating 
NK cell receptors with their respective ligands or interaction of CD16 with antibodies that 
have specifically bound to cellular target antigens, NK cell-mediated induction of apoptosis 
is based on the release of the pre-stored effector molecules granzyme B and perforin from 
Introduction 
 
10 
 
cytotoxic granules into the immunological synapse that is formed between NK cell and 
target cell. Although the exact delivery mechanism of the effector molecules into the target 
cell is not completely understood, perforin is thought to form a pore within the target cell 
membrane by polymerization making the cytoplasm of the target cell accessible for 
granzyme B [110].  
  The human serine protease family of granzymes consists of granzymes A, B, H, K 
and M [111]. As one of the most abundant granzymes, granzyme B is one of the major 
components of cytolytic granules. Inside the target cell granzyme B-mediated apoptosis 
can be induced by direct activation of the executioner procaspases-3 and -7, resulting in 
activation of the executioner procaspase-6 and subsequent cleavage of multiple 
intracellular proteins. Further, granzyme B can directly cleave intracellular housekeeping 
proteins, such as cytoskeleton components, and is able to translocate into the nucleus to 
activate the DNA-fragmentation factor (DFF), which induces target cell death. On the other 
hand, the intrinsic mitochondrial death pathway is an alternative mechanism, by which 
granzyme B can induce apoptosis in target cells. This is initiated by cleavage of Bid and/or 
the Mcl-1/Bim complex, resulting in oligomerization of BAX and/or BAK in the outer 
mitochondrial membrane, which mediates the release of pro-apoptotic proteins such as 
cytochrome c (cyt-c) into the cytoplasm. Interaction of cyt-c and the apoptotic protease 
activating factor-1 (Apaf-1) induces formation of the apoptosome that in turn activates pro-
caspase-9 [112].    
  In addition to target cell lysis mediated by ADCC or activating signaling via the above 
described activating receptors, NK cells can induce apoptosis in target cells via the death 
receptor pathway. The group of death receptors belongs to the tumor necrosis factor 
receptor (TNFR) superfamily and consists of six different death receptors [TNFR1 (DR1), 
Fas (CD95, DR2), DR3, DR4 (TRAIL-R1), DR5 (TRAIL-R2), DR6], all of which express a 
characteristic death domain (DD) in their cytoplasmic portion. Upon engagement of these 
death receptors with their ligands (TNF, FasL and TRAIL) expressed on NK cells, 
oligomerization of receptors and subsequent recruitment of Fas-associated death domain 
adaptor protein (FADD) and procaspase-8 and -10 result in formation of the death-inducing 
signaling complex (DISC). Within the context of DISC, procaspase-8 and -10 are cleaved 
into their active form and released into the cytoplasm. Caspase-8 and -10 promote 
apoptosis either via direct activation of executioner caspases-3 and -7 or induction of the 
mitochondrial death pathway [113, 114]. Based on the variety of pathways by which NK 
cells can be activated and subsequently lyse malignant cells, NK cells are an attractive 
effector cell population for immunotherapy. Since functionality or NK cell counts can be 
negatively affected in cancer patients, NK cell lines are an alternative NK cell source. The 
Introduction 
 
11 
 
GD2-directed immunotherapeutic approach evaluated in the present study is based on 
CAR-mediated redirection and adoptive transfer of the human NK cell line NK-92. 
1.5. NK-92 
  The human NK cell line NK-92 was generated from a 50-year-old patient with Non-
Hodgkin’s lymphoma and exhibits phenotypical and functional characteristics of activated 
NK cells [115]. NK-92 cells have been shown to mediate high cytotoxicity towards a variety 
of tumor cell lines as well as primary tumor cells [116-118]. Characterization of surface 
marker expression revealed expression of CD56bright, CD2, CD7, CD11a, CD28, CD45 and 
CD54, whereas expression of CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, 
CD20, CD23, CD34 and HLA-DR could not be detected. Survival and growth of NK-92 are 
IL-2 dependent [116]. Due to lack of expression of the low affinity IgG Fc receptors CD16 
and CD32 as well as the high IgG affinity receptor CD64, NK-92 are not capable of 
mediating ADCC by themselves [119]. Regarding the expression of activating NK cell 
receptors, it has been shown that NK-92 express NKp30, NKp46, 2B4 and NKG2D. 
Further, NK-92 cells express TRAIL, TNF-α and low levels of FasL, indicating that they are 
able to mediate cytotoxicity using the death receptor/death receptor ligand pathway [119]. 
Expression of the majority of inhibitory NK cell receptors in particular of KIRs is absent on 
NK-92. The only exceptions are KIR2DL4, which is an unusual KIR and has been shown to 
mediate inhibitory as well as activating signaling [120] and the CD94/NKG2A heterodimer 
[119]. Importantly, despite the lack of inhibitory receptors, NK-92 do not mediate 
cytotoxicity towards non-malignant allogeneic cells or negatively affect the normal 
proliferative potential of hematopoietic cells [116].  
  All the above mentioned characteristics, and the fact that NK-92 can be easily 
expanded under good manufacturing practice conditions (GMP) [121, 122], support NK-92 
as an interesting effector cell line for an immunotherapeutic approach. Regarding the 
safety of an NK-92 application, irradiation of NK-92 cells with 500 cGy was found to 
prevent cell proliferation while retaining cytotoxic activity [123]. So far, safety and 
tolerability of an application of irradiated NK-92 in patients has been shown in a clinical 
phase I trial [124]. Recently, the application of NK-92 in a phase I trial demonstrated 
persistence of NK-92 for up to 48 hours after infusion and showed some responses in 
patients with advanced lung cancer [125]. To address the problem of NK cell resistance 
due to reduced expression or release of activating NK cell ligands on tumor cells, and to 
specifically direct this highly cytotoxic NK cell line towards distinct tumor entities, NK-92 
can be genetically engineered to express TAA-specific chimeric antigen receptors. 
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1.6. Chimeric antigen receptors  
  The concept of chimeric antigen receptors (CARs) was developed to combine two 
existing immunotherapeutic approaches, the targeting of a specific antigen with an 
antibody and the adoptive transfer of immune effector cells. This is based on the idea that 
a combination of the specificity of an antibody and the ability of effector cells to penetrate 
tissues and to directly mediate cytotoxicity towards target cells would further improve 
therapeutic potential. The first chimeric antigen receptors were designed as a combination 
of variable regions of the heavy and the light chain (VH and VL) of an antibody and the 
extracellular constant regions as well as the transmembrane and cytoplasmic domains of a 
T cell receptor (TCR) [126]. Although these chimeric T cell receptors had been shown to be 
functional, further improvements were made to create CARs, consisting of single chain 
fragments (scFv) for antigen recognition, which are connected via a hinge region to signal-
transducing receptor subunits, such as the CD3 ζ-chain or the FcγRIII γ-chain. Single chain 
fragments contain the variable regions of the heavy (VH) and the light chain (VL) of an 
antibody, connected by a flexible linker [127, 128]. Specificity and affinity of such single 
chain fragments have been shown to be comparable to the Fab fragment of the respective 
antibody [129].  
  Further improvements had been made to these first generation CARs, resulting in 
second generation CARs which include an additional costimulatory signaling domain such 
as CD28, CD134 (OX40) or CD137 (4-1BB), and third generation CARs that contain a 
combination of several additional costimulatory signaling domains (Fig. 1.6) [130-132]. 
Inclusion of these additional costimulatory domains could increase cytotoxic activity and 
cytokine production, as well as trafficking and persistence of CAR-expressing effector cells 
[132-134].  
  Different methods have been employed for genetic engineering of effector cells. 
Permanent expression of the CAR-transgene in effector cells can be achieved by the use 
of retroviral or lentiviral vectors [135, 136]. Additionally, approaches based on 
electroporation to transfect effector cells with mRNA were successful in inducing transient 
expression of the CAR-transgene [137]. 
  The concept of chimeric antigen receptors has great potential for cancer 
immunotherapy, since expression of CARs especially on T cells enables these effector 
cells to specifically target a broader range of surface TAA in addition to proteins, including 
sugars or lipids, which they could otherwise not recognize by their conventional MHC-
restricted mechanism of antigen recognition. This is particularly important with regard to the 
down-regulated/decreased MHC class I expression by which tumor cells can escape 
immune recognition. 
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Figure 1.6: Chimeric antigen receptor (CAR) generations (adapted from [138]). First generation CARs 
consist of an antigen-specific single chain fragment variable (blue), a hinge region (red) to separate the scFv 
from the transmembrane domain, a transmembrane domain (gray), and an intracellular signal-transducing 
domain, such as the CD3 ζ-chain or the FcγRIII γ-chain (black). Second generation and third generation CARs 
additionally include one or multiple costimulatory signaling domains (yellow, green), such as CD28, CD134 
(OX40) or CD137 (4-1BB), respectively.   
  
  In addition to T cells, NK cells are promising effector cells for CAR-based 
immunotherapeutic approaches. MHC class I downregulation, such as in the case of NB, 
already renders tumors susceptible to NK cell-mediated cytotoxicity due to lack of inhibitory 
signals mediated in healthy tissues by the interaction of MHC class I molecules and 
inhibitory KIR receptors on NK cells. Since activating NK cell receptors are germline 
encoded, recognition of target cells is restricted to a limited number of conserved activating 
ligands on tumor cells. Hence, genetic engineering of NK cells to express a CAR will highly 
increase specificity of NK cells to a broad range of surface TAA on tumor cells. This has 
the potential to address the problem of immune evasion by down-regulation or shedding of 
activating ligands on tumor cells.  
  So far, CAR-expressing effector cells have been generated to specifically target 
different TAAs, such as ErbB2, CD20, CD19 and GD2 [139-144]. Importantly, CAR-
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expressing effector cells have already entered clinical trials and have shown some 
promising results [145-147]. In the present study, CAR technology was employed to 
expand passive immunotherapy directed against GD2 as NB-associated target antigen to a 
cellular approach based on NK cells as effector cells. In particular, NK-92 were genetically 
modified to express a GD2-specific CAR (NK-92-scFv(ch14.18)-zeta. 
1.7. NK-92-scFv(ch14.18)-zeta 
  The concept of genetic engineering of immune effector cells to express a CAR was 
employed to combine passive immunotherapeutic approaches based on TAA-specific 
antibodies with the application of the human NK cell line NK-92, which has been 
demonstrated to be safe and well tolerated, with some responses in patients [122, 124, 
125]. So far, CAR-expressing NK-92 cell lines have been generated towards a variety of 
TAAs, such as CD20 or CD19 in lymphoma and leukemia cells and ErbB2 or EpCAM in 
tumors of epithelial origin. The efficacy of these cell lines has been demonstrated in pre-
clinical in vitro and in vivo studies [140, 142, 148, 149].  
  Since GD2-specific passive immunotherapeutic approaches based on the application 
of the GD2-specific antibody ch14.18 have been shown to significantly improve survival of 
high-risk NB patients [74], the GD2-specific NK cell line NK-92-scFv(ch14.18)-zeta was 
generated to extend the approach of CAR-expressing NK-92 to an application in NB.  
  NK-92-scFv(ch14.18)-zeta was previously generated by genetic engineering of 
parental NK-92 cells to express a GD2-specific chimeric antigen receptor [150]. GD2-
specificity of this CAR is mediated by a single chain fragment (scFv(ch14.18)), containing 
the variable regions of the heavy (VH) and the light chain (VL) of the GD2-specific antibody 
ch14.18, connected by a synthetic flexible linker ((G4S)4). A CD8α hinge region connects 
the scFv to an extracellular Myc-tag, which is included to enable detection of the expressed 
CAR on the surface of transduced cells.   
  Signal-transduction is mediated by the CD3 ζ-chain, which is linked to the Myc-tag. 
Further, the neomycin-resistance gene is included in the vector to enable selection of 
successfully transduced cells by addition of G418 in the culture media [150]. Positions of all 
components within the retroviral vector pLXSN are shown in Figure 1.7.   
  Since it was unknown, whether orientation of VH and VL might affect functionality of 
the resulting CAR, vectors with both orientations were used for the generation of NK-92-
scFv(ch14.18)-zeta as described previously [150]. No differences in expression of CARs 
with both orientations were observed. Hence, we received the clone with the VHVL 
orientation from the collaborating lab to perform the experiments presented in this study.  
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Figure 1.7: Retroviral vector encoding for GD2-specific CAR (scFv(ch14.18)-zeta) [150, modified].  
Expression of scFv(ch14.18)-zeta is controlled by a 5’LTR (long terminal repeat; from moloney murine leukemia 
virus). N-terminal immunoglobulin heavy chain leader peptide SP (signal peptide) is followed by the single chain 
fragment containing the variable regions of the heavy and the light chain of ch14.18 (scFv(ch14.18), a Myc-tag, 
CD8α hinge region and the CD3 ζ-chain. Additionally, the SV40 promotor drives the expression of a neomycin 
resistance gene, which was included for selection of transduced cells with G418. 
  
  In theory, these newly generated NK-92-scFv(ch14.18)-zeta should be able to 
mediate cytotoxicity towards tumor cells by either one or a combination of three different 
ways in the absence of inhibitory signaling due to lack of inhibitory receptors: (1) activation 
by interaction of activating NK receptors with respective ligands on tumor cells, (2) 
activation by engagement of the CAR with the TAA GD2, both of which result in the release 
of the effector molecules granzyme B and perforin, and (3) induction of apoptosis in tumor 
cells by interaction of death receptor ligands on NK cells with death receptors expressed 
on tumor cells. 
1.8. Aim of this study 
  The treatment of high-risk NB is particularly challenging due to the development of 
drug-resistance during induction and consolidation therapy. Drug resistance associated 
with progressive disease and in particular MRD, which can cause a relapse, is a major 
challenge in the treatment of high-risk NB with conventional therapies. Although passive 
immunotherapeutic approaches targeting the TAA GD2 have recently shown promising 
results, there is still need for the development of new and more effective treatment 
strategies to further improve survival of high-risk patients.  
  Therefore, this study aims at analyzing the mechanism and the efficacy of a GD2-
specific cellular therapy with NK cells. For this purpose, we employed NK-92-
scFv(ch14.18)-zeta cells. Expression of the GD2-specific CAR should enable NK-92-
scFv(ch14.18)-zeta to overcome evasion mechanisms developed by the tumor. Within this 
study we wanted to evaluate in detail, GD2-specificity, and the role of the interaction 
between CAR and GD2 in both activation of NK-92-scFv(ch14.18)-zeta and lysis mediated 
by NK-92-scFv(ch14.18)-zeta. Additionally, in vivo therapeutic efficacy of NK-92-
scFv(ch14.18)-zeta was determined in a drug-resistant xenograft mouse model.  
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2. Material and Methods 
2.1. Material 
2.1.1. Chemicals and supplements 
Product   Provider 
   
Acrylamide Bisphosphate  BioRad, Munich, Germany 
   
Ammoniumpersulfate  BioRad, Munich, Germany 
   
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim, Germany 
   
Calcein-AM  Sigma-Aldrich, Steinheim, Germany 
   
51Chromium  PerkinElmer, Billerica, MA, USA 
   
Diamino-phenylindole (DAPI) Sigma-Aldrich, Steinheim, Germany 
   
Dimethylsulfoxide (DMSO) WAK Chemie Medical GmbH, 
Steinbach, Germany 
   
Ethanol ≥ 99.8%  Carl Roth GmbH, Karlsruhe, Germany 
   
Ethylenediaminetetraacetic 
acid 
(EDTA) Carl Roth GmbH, Karlsruhe, Germany 
   
GM2  Sigma-Aldrich, Steinheim, Germany 
   
GD2 (disialoganglioside) Sigma-Aldrich, Steinheim, Germany 
   
Human albumin  CSL Behring GmbH, Marburg, 
Germany 
   
Ionomycin  Sigma-Aldrich, Steinheim, Germany 
   
Methanol ≥ 99.9%  Carl Roth GmbH, Karlsruhe, Germany 
   
2-mercaptoethanol  Sigma-Aldrich, Steinheim, Germany 
   
Phosphate buffered saline (PBS) PAA, Pasching, Austria 
w/o Ca2+ and Mg2+ 
   
Phorbol myristate acetate PMA Calbiochem, EMD Biosciences Inc., La 
Jolla, CA, USA 
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1-Phenyl-2-
hexadecanoylamino-3-
pyrrolidino-1-propanol 
(PPPP) Dr. Barry Maurer, Texas Tech 
University, Health Sciences Center 
Cancer Center, Lubbock, TX, USA 
   
2-Propanol  Carl Roth GmbH, Karlsruhe, Germany 
   
Propidiumiodide (PI) Molecular Probes, Life Technologies, 
Darmstadt, Germany 
   
Sodium azide NaN3 Carl Roth GmbH, Karlsruhe, Germany 
   
Sodium chloride  Merck KGaA, Darmstadt, Germany 
   
Sodium dodecyl sulphate (SDS) BioRad, Munich, Germany 
   
Sulphuric acid (H2SO4) Carl Roth GmbH, Karlsruhe, Germany 
   
N,N,N`,N`tetra-methyl-
ethylendiamine 
(TEMED) BioRad, Munich, Germany 
   
Tris-HCl  BioRad, Munich, Germany 
   
Triton-X-100  Carl Roth GmbH, Karlsruhe, Germany 
   
Tween-20  BioRad, Munich, Germany 
 
2.1.2. Cell culture media und supplements 
Cell culture medium   Provider 
   
IMDM  PAA, Pasching, Austria 
   
RPMI 1640  PAA, Pasching, Austria 
   
X-VIVO-10 
 
Biozym Scientific GmbH,  
Hessisch Oldendorf, Germany 
   
Supplement   Provider 
   
Fetal bovine serum (FBS) PAN-Biotech, Aidenbach, Germany 
   
Geneticin (G418) Sigma-Aldrich, Steinheim, Germany 
   
Human serum AB converted PAA, Pasching, Austria 
   
Interleukin-2 (Aldesleukin,  
18x106 IU/ml) 
Novartis, Nuremberg, Germany 
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ITS (1000x) (ITS, 5 mg/ml 
insulin,  
5 mg/ml 
transferrin,  
5 μg/ml selenious 
acid) 
BD Biosciences, Heidelberg, Germany 
   
Penicillin/Streptomycin 10,000 IU/ml /  
10 mg/ml 
PAA, Pasching, Austria 
   
Stable glutamine 200 mM PAA, Pasching, Austria 
 
2.1.3. Special laboratory reagents and buffers 
Product   Provider 
   
Trypan blue 0.4%  Sigma-Aldrich, Steinheim, Germany 
   
0.05% Trypsin/EDTA  PAA, Pasching, Austria 
   
Protease inhibitor cocktail  Sigma-Aldrich, Steinheim, Germany 
   
BioRad protein assay  BIO-RAD, Munich, Germany 
   
Laemmli sample buffer  BioRad, Munich, Germany 
   
SpectraTM Multicolor Broad 
Range Protein Ladder 
 Thermo Scientific, Erlangen, Germany 
   
MatrigelTM Basement 
Membrane Matrix 
 BD Biosciences, Heidelberg, Germany 
   
Immun-Star- HRP peroxide 
buffer 
 BioRad, Munich, Germany 
   
Immun-Star-HRP 
luminol/enhancer 
 BioRad, Munich, Germany 
2.1.4. Kits 
Human granzyme B  
ELISA Kit 
Cat# 3485-1H-20 MabTech, Hamburg, Germany 
   
Human perforin  
ELISA Kit 
Cat# 3465-1H-20 MabTech, Hamburg, Germany 
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2.1.5. Antibodies 
Primary antibodies 
antigen clone/name isotype conjugate Cat # provider 
            
GD2 ch14.18/CHO human 
IgG1 
purified / Polymun, Vienna, 
Austria 
      
14G2a Id14G2a-17-9 
(anti-IdAb, 
ganglidiomab) 
mouse 
IgG1, κ  
purified / BioGenes, Berlin, 
Germany 
      
Myc-tag 9E10 mouse 
IgG1, κ  
purified SAB4700447 Sigma-Aldrich, 
Steinheim, Germany 
      
GCS 1E5 mouse 
IgG1, κ  
purified H00007357-
M03 
Abnova, Heidelberg, 
Germany 
      
β-actin AC-15 mouse 
IgG1, κ  
HRP A3854 Sigma-Aldrich, 
Steinheim, Germany 
            
Isotype controls 
isotype clone/name conjugate Cat # provider 
      
human 
IgG1 
Rituximab/MabThera purified / Roche, Mannheim, 
Germany 
      
mouse 
IgG1 
11711 purified MAB002 R&D systems, 
Wiesbaden-
Nordenstadt, 
Germany 
            
Secondary antibodies 
specificity clone/name isotype conjugate Cat # provider 
      
human-
IgG 
G18-145 Mouse 
IgG1 
PE 555787 BD Biosciences 
      
mouse 
IgG1 
A85-1 Rat 
IgG1 
PE 550083 BD Biosciences 
      
mouse  
IgG1 
/ goat HRP 170-6516 BioRad, Munich, 
Germany 
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2.1.6. Cell culture media and buffers preparations 
Cell culture media 
RPMI 1640 
  
10% FBS 
  
100 IU/ml Penicillin 
  
0.1 mg/ml Streptomycin 
  
IMDM 
  
20% FBS 
  
1 x ITS (5 μg/ml Insulin, 5 μg/ml transferrin, 5 
ng/ml selenious acid) 
  
4 mM stable glutamine 
  
X-VIVO-10 
  
5% human serum, type AB, converted 
  
100 IU/ml IL-2 (Aldesleukin) 
  
0.6 mg/ml G418 (Geneticin) 
    
Western blot buffers 
Resolving gel buffer pH 8,8 
  
1.5 M Tris-HCl 
  
0.4% SDS 
  
Stacking gel buffer pH 6.8 
    
0.5 M Tris-HCl 
  
0.4% SDS 
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Running buffer 
  
25 mM Tris 
  
192 mM Glycin 
  
0.1% SDS 
  
Washing buffer (TTBS) pH 7.5 
  
20 mM Tris 
  
150 mM NaCl 
  
0.05% Tween 20 
  
Blocking buffer 
  
 PBS 
  
1x Roti-Block 
  
Transfer buffer (Towbin buffer) pH 8.3 
  
25 mM Tris 
  
192 mM Glycin 
  
5% Methanol 
  
Lysis buffer 
  
10 mM Tris 
  
10 mM NaCl 
  
0.1 mM EDTA 
  
0.5% Triton-X 100 
  
0.02% NaN3 
 
 
 
 
 
Material and Methods 
 
22 
 
FACS buffer 
  
  
 PBS 
  
1% BSA 
  
0.1% EDTA 
  
0.1% NaN3 
    
ELISA buffers 
Washing buffer  
  
 PBS 
  
0.05% TWEEN 20 
  
  
Assay diluent 
  
 PBS 
  
0.1% BSA  
 
2.1.7. Special laboratory tools 
Protran nitrocellulose transfer 
membrane 
Whatman GmbH, Dassel, Germany 
  
Mini trans-blot filter paper BioRad, Munich, Germany 
  
70 μm cell strainer BD Biosciences, Heidelberg, Germany 
 
2.1.8. Special laboratory equipment 
Synergy HT multi-mode  
microplate reader 
BioTek, Bad Friedrichshall, Germany 
  
FACS Canto II BD Biosciences, Heidelberg, Germany 
  
Wizard 2 Gamma counter PerkinElmer, Billerica, MA, USA 
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Mini Trans-Blot® Electrophoretic  
Transfer Cell 
BioRad, Munich, Germany 
  
Mini-PROTEAN® cell BioRad, Munich, Germany 
  
ChemiDocTM XRS+ Molecular Imager BioRad, Munich, Germany 
 
2.1.9. Softwares 
FlowJo 7.6 Treestar, Ashland,OR 
  
FACSDiva 6.1.3 BD Biosciences, Heidelberg, Germany 
  
GraphPad Prism 5.01 GraphPad software, San Diego, CA 
  
Sigma Plot 10.0 Systat Software GmbH,  
Erkrath, Germany 
 
2.1.10. Cell lines 
  All NB cell lines (LA-N-1, LA-N-5, SK-N-BE(1), SK-N-BE(2), CHLA-15, CHLA-20, 
CHLA-79, CHLA-136, SMS-KAN, SMS-KANR, SMS-KCN, SMS-KCNR, SK-N-SH) and the 
erythroleukemia cell line K562 were kindly provided by Dr. Reynolds’ laboratory (Texas 
Tech University, Health Sciences Center Cancer Center, Lubbock, TX, USA), which 
houses the Children’s Oncology Group (COG) cell line repository. Some of the NB cell 
lines used were generated from the same patient at different points in therapy and are 
referred to as cell line pairs. The cell lines SK-N-BE(1), SMS-KAN, SMS-KCN and CHLA-
15 were established at time point of diagnosis. SK-N-BE(2), SMS-KANR, SMS-KCNR and 
CHLA-20 were generated from relapse tumor material of the same patient, respectively. 
Drug resistance patterns of the above mentioned NB cell lines had been analyzed in 
previous studies. These reported drug resistance of CHLA-20 and multidrug resistance of 
SK-N-BE(2), CHLA-79 and CHLA-136 [16, 151, 152]. 
  The parental human NK cell line NK-92, as well as the empty vector control cell line 
NK-92-pLXSN, ErbB2-specific NK-92-scFv(FRP5)-zeta [140] and GD2-specific NK-92-
scFv(ch14.18)-zeta [150], were kindly provided by Prof. Wels (Georg-Speyer-Haus, 
Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany). 
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2.2. Methods 
2.2.1. Cell culture 
  All cell lines were cultured under standard conditions (37°C, 100% relative humidity, 
5% CO2, 95% air). The human NB cell lines SK-N-BE(1), SK-N-BE(2), SMS-KAN, SMS-
KANR, SMS-KCN, SMS-KCNR, LA-N-1, LA-N-5, SK-N-SH as well as the human 
erythroleukemia cell line K562 were cultured in RPMI 1640 supplemented with 10% heat-
inactivated FBS, 100 IU/ml Penicillin and 0.1 mg/ml Streptomycin. CHLA-15, CHLA-20, 
CHLA-79 and CHLA-136 were cultured in IMDM supplemented with 20% heat-inactivated 
FBS, 4 mM glutamine, 1x ITS, 100 IU/ml Penicillin and 0.1 mg/ml Streptomycin.  
  The parental human NK cell line NK-92 was cultured in X-VIVO-10 supplemented 
with 5% heat-inactivated human AB serum and 100 IU/ml human recombinant IL-2. X-
VIVO-10 containing 5% heat-inactivated human AB serum, 100 IU/ml human recombinant 
IL-2 and 0.6 mg/ml G418 was used to culture NK-92-pLXSN, NK-92-scFv(FRP5)-zeta as 
well as NK-92-scFv(ch14.18)-zeta.  
  Adherent cells were subcultured at 80-90% confluency using 0.05% Trypsin/EDTA. 
For cryoconservation, NB cells and K562 were frozen in human albumin containing 10% 
DMSO at a concentration of 3-6x106 cells/ml. NK cells were frozen in X-VIVO-10 containing 
5% human AB serum, 100 IU/ml IL-2 and 10% DMSO at a concentration of 5x106 cells/ml. 
For optimal viability, cells were frozen at -80°C for 72 h at a cooling rate of -1°C to -3°C/min 
using an isopropanol chamber. After 72 h, cells were transferred to a liquid nitrogen tank 
for long-term storage. Identities of all NB cell lines, K562 and NK-92 were verified by 
analysis of short tandem repeats (STR), as described in the literature [153], and verified 
against the COG cell line STR database. Further, all cell lines were routinely tested for 
mycoplasma contamination using the MycoAlert-Assay from LONZA (Walkersville, MD, 
USA).  
2.2.2. PPPP-treatment of NB cell lines 
  To determine the impact of GD2 recognition on NK-92-scFv(ch14.18)-zeta-mediated 
lysis of NB tumor cells, GD2-expression was inhibited by pre-treating cells with the 
selective glucolysceramide synthase (GCS) inhibitor PPPP (1-phenyl-2-
hexadecanoylamino-3-pyrrolidino-1-propanol, kindly provided by Dr. Barry Maurer, Texas 
Tech University, Health Sciences Center Cancer Center, Lubbock, TX, USA, [154]). GCS 
catalyzes the conversion of ceramides into glucosylceramides, which is the first step in 
GD2-synthesis. For PPPP-treatment NB cells (CHLA-20 and SK-N-BE(2)) were seeded 
into a 6-well plate at a concentration of 1x106 cells in 3 ml/well and allowed to attach 
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overnight. PPPP was added in a final concentration of 1 μM. Control cells were treated with 
the same volume of 100% EtOH (vehicle control). Cells were incubated with PPPP or 
vehicle control for three days. GD2-expression was confirmed using flow cytometry and 
sensitivity towards NK-92-scFv(ch14.18)-zeta-mediated lysis was analyzed in 51Cr release 
cytotoxicity assays as described below. 
2.2.3. Flow cytometry 
  Exclusion of dead cells in flow cytometric analyses was done by addition of PI or 
DAPI prior to sample acquisition, at a concentration of 1 mg/ml and 0.1 mg/ml, 
respectively. Flow cytometric analyses were performed at a BD FACS CANTOII using 
FACSDiva software (BD Biosciences, Heidelberg, Germany), and data was analyzed using 
FlowJo (Treestar, Ashland, OR, USA). 
2.2.3.1. Flow cytometric analysis of CAR-expression  
  CAR surface expression can be analyzed with two different staining strategies. For 
analysis based on Myc-tag-expression within the extracellular part of the CAR, cells were 
incubated with anti-Myc-tag antibody (1 μg/1x106 cells, diluted in FACS buffer) in a total 
volume of 100 μl for 30 min on ice in the dark. For analysis of GD2-specific CAR-
expression, NK cells were stained with the anti-idiotype antibody (anti-IdAb) ganglidiomab 
[50] (Id14G2A-17-9, 1 μg/1x106 cells) in a total volume of 100 μl for 30 min on ice in the 
dark. Due to its anti-idiotype characteristics, ganglidiomab specifically binds the paratopes 
of the GD2-specific CAR. Purified mouse IgG1 (1 μg/1x106 cells) was utilized as isotype 
control. Cells were washed with 1 ml FACS buffer and centrifuged (300x g, 5 min, RT). 
Supernatant was discarded, and cells were incubated with PE-labeled rat anti-mouse IgG1 
antibody (1:200) in a total volume of 100 μl for 20 min on ice in the dark. Cells were 
washed with 1 ml of FACS buffer and centrifuged (300x g, 5 min, RT). Supernatant was 
discarded; cells were resuspended in 500 μl FACS buffer and transferred into a FACS 
tube. For each sample, 20,000 live cells were analyzed. 
  To analyze the effect of IL-2 starvation on CAR expression, cells were cultured for 
four days in X-VIVO-10 with 5% human serum and 0.6 mg/ml G418 (IL-2 starvation) or in 
X-VIVO-10 containing 5% human serum, 0.6 mg/ml G418 and 100 IU/ml IL-2 (complete). 
Starvation was abrogated after four days by addition of IL-2 and culture of cells for two 
additional days.   
2.2.3.2. Flow cytometric analysis of GD2-expression  
  For analysis of GD2 surface expression, cells were stained with ch14.18/CHO 
(1 μg/1x106 cells, diluted in FACS buffer) in a total volume of 100 μl for 20 min on ice in the 
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dark. The chimeric anti-CD20 antibody rituximab (1 μg/1x106 cells) was used as isotype 
control for ch14.18. Cells were washed with 1 ml FACS buffer and centrifuged (300x g, 
5 min, RT). Supernatant was discarded and cells were incubated with PE-labeled mouse 
anti-human IgG antibody (1:5, diluted in FACS buffer) in a volume of 100 μl for 20 min on 
ice in the dark. Cells were washed with 1 ml FACS buffer, centrifuged (300x g, 5 min, RT) 
and supernatant was discarded. Cells were then resuspended in 500 μl FACS buffer and 
transferred to a FACS tube for flow cytometric analysis. Ch14.18/CHO was kindly provided 
by the SIOPEN (International Society of Pediatric Oncology Europe Neuroblastoma) group. 
For each sample, 20,000 live cells were analyzed. 
2.2.4. Cytotoxicity assays 
  Two different kinds of cytotoxicity assays were employed to analyze the cytotoxic 
activity of NK-92-scFv(ch14.18)-zeta as well as control NK cell lines. The 51Cr release 
assay is a radioactive cytotoxicity assay based on the labeling of target cells with 51Cr prior 
to co-incubation with effector cells. Killing of target cells then results in release of 
radioactive 51Cr that can be detected in the supernatant with a gamma counter. 
Alternatively, the calcein release cytotoxicity assay is a non-radioactive cytotoxicity assay 
and based on the labeling of target cells with calcein-acetoxymethylester (calcein-AM). 
Within the cell, calcein-AM is converted by intracellular esterases to calcein, which cannot 
passively cross the intact cell membrane. Effector cell-mediated cell killing results in 
release of calcein from dead cells into the supernatant. Calcein is a fluorescent dye with an 
excitation maximum at a wavelength of 495 nm and an emission maximum at 515 nm. 
Fluorescence of calcein in the supernatant can be measured with a microplate reader 
(filters: 485/20 and 528/20). 
2.2.4.1. 51Cr release cytotoxicity assay 
  51Cr release cytotoxicity assay was used to analyze the cytotoxicity of NK-92-
scFv(ch14.18)-zeta and parental NK-92 or empty vector control NK-92-pLXSN towards 
GD2-positive cell lines (CHLA-136, CHLA-79, CHLA-20, SK-N-BE(2), LA-N-1, LA-N-5). 
Further, sensitivity of NB cell line pairs of four patients (SK-N-BE(1)/SK-N-BE(2), SMS-
KAN/SMS-KANR, SMS-KCN/SMS-KCNR, CHLA-15/CHLA-20) towards NK-92-
scFv(ch14.18)-zeta and control NK cell line-mediated cytotoxicity was compared. 51Cr 
release assays were also performed to determine effect of inhibition of GCS and thereby 
GD2-expression on sensitivity of PPPP or vehicle pre-treated CHLA-20 and SK-N-BE(2) 
target cells towards NK-92-scFv(ch14-18)-zeta and control NK cell line-mediated 
cytotoxicity.  
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  Target cells were loaded with 51Cr (0.125 mCi/5x105 cells in 500 μl) and incubated for 
two hours at 37°C. Cells were washed twice with X-VIVO-10 containing 5% heat-
inactivated human AB serum and 5x103 target cells were then co-incubated with effector 
cells at an E:T ratio of 6.3:1 in a final volume of 200 μl. Maximum release was induced by 
addition of 5% SDS solution to target cell suspension. To assess for spontaneous 51Cr 
release 5x103 target cells were incubated without NK cells. After incubation for six hours, 
50 μl of supernatant were transferred into a test tube, and radioactivity was measured 
using a gamma counter Wizard 2 (PerkinElmer, Billerica, MA, USA). Specific cytotoxicity 
was calculated according to the formula:  
((experimental lysis – spontaneous lysis) / (maximal lysis – spontaneous lysis)) x 100. 
  To block CAR-mediated lysis, 10 μg/ml anti-IdAb ganglidiomab were added during 
co-incubation of NK-92-scFv(ch14.18)-zeta with either LA-N-5 or LA-N-1. Purified mouse 
IgG1 (10 μg/ml) was used as isotype control.   
 2.2.4.2 Calcein release cytotoxicity assay 
  The calcein release cytotoxicity assay was used to determine an appropriate E:T ratio 
in assays with CHLA-20 as target cells. Further, the cytotoxic activity of NK-92-
scFv(ch14.18)-zeta and control cell lines towards GD2+ CHLA-20 and GD2- SK-N-SH was 
analyzed using calcein release assays. The effect of CAR-blocking as well as the effect of 
blocking the target antigen GD2 on NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2+ 
CHLA-15 and CHLA-20 in comparison to GD2- K562 were further analyzed with this assay. 
  For calcein labeling 6x105 target cells were resuspended in 1 ml PBS/12.5% FBS, 
and calcein-AM was added at a final concentration of 10 μM. Cells were incubated shaking 
(100 rpm) for 30 min at 37°C, without CO2 and then washed twice with PBS/12.5% FBS. 
Next, cells were washed once in X-VIVO-10 containing 5% heat-inactivated human AB 
serum, centrifuged (300x g, 5 min, RT). Target cells were then resuspended in 12 ml X-
VIVO-10/5% heat-inactivated human serum for a final concentration of 5x103 cells/100 μl 
per well. Effector cells were washed once in X-VIVO-10/5% heat-inactivated human serum 
and resuspended in X-VIVO-10/5% heat-inactivated human serum at a final concentration 
of 3.15x104 cells/100 μl/well for an E:T ratio of 6.3:1. For maximal calcein release, target 
cell suspension was diluted 1:2 in X-VIVO-10/5% human serum, treated with ultrasound for 
30 s and then 200 μl/well were added to respective wells. After incubation for five hours at 
37°C without CO2, 96-well plates were centrifuged (300x g, 5 min, RT) and 50 μl of 
supernatant were transferred into a black 96-well plate. Calcein fluorescence in 
supernatants was then analyzed at an excitation wavelength of 495 nm and emission 
wavelength of 515 nm using a microplate reader. Specific cytotoxicity was calculated 
Material and Methods 
 
28 
 
according to the formula: ((experimental lysis – spontaneous lysis) / (maximal lysis – 
spontaneous lysis)) x 100. 
  Blocking of the CAR during co-incubation of target cells and NK-92-scFv(ch14.18)-
zeta was accomplished by addition of 10 μg/ml anti-IdAb ganglidiomab or mouse IgG1 as 
the isotype control. 
  The target antigen GD2 was blocked by addition of the GD2-specific antibody 
ch14.18/CHO during co-incubation with effector cells at a final concentration of 10 μg/ml. 
Chimeric CD20-specific antibody rituximab (10 μg/ml) was used as the isotype control. 
2.2.5. Granzyme B and Perforin ELISA 
  Granzyme B and perforin production of NK-92-scFv(ch14.18)-zeta and NK-92-pLXSN 
in response to activation with immobilized GD2 were analyzed with ELISA. Therefore, NK 
cells were incubated with 100 ng plate-bound GD2. The same amounts of GM2 were used 
as an unspecific control. Immobilization of gangliosides was achieved by incubation of 
100 ng GD2 (100 μl, 1 ng/μl) or GM2 (100 μl, 1 ng/μl) in 100% methanol/well in a 24-well 
plate for one hour at 56°C to evaporate the methanol. 5x105 NK-92-scFv(ch14.18)-zeta or 
NK-92-pLXSN were added in a total volume of 500 μl X-VIVO-10 containing 5% heat-
inactivated human serum, and incubated for six hours at 37°C. As a positive control, NK 
cells were stimulated with 10 ng/ml PMA and 1 μg/ml Ionomycin.  
  To block GD2-induced granzyme B and perforin production, the anti-IdAb  
ganglidiomab was added at a final concentration of 10 μg/ml during incubation. Purified 
mouse IgG1 was utilized as an isotype control for ganglidiomab. After six hours, 500 μl of 
supernatant were collected, centrifuged (300x g, 5 min, RT) and stored at -80°C until 
further analysis with ELISA.  
  Granzyme B and perforin concentrations were determined using granzyme B and 
perforin ELISA kits. For this purpose, a 96-well ELISA plate was coated with either 
monoclonal anti-granzyme B antibody (GB10, 150 ng/well in 100 μl) or monoclonal anti-
perforin antibody (Pf-80/164, 200 ng/well in 100 μl) and incubated overnight at 4°C. The 
next day, plates were washed twice with washing buffer and incubated with 200 μl/well 
assay diluent for one hour at room temperature to block unspecific binding. After washing 
plates three times with washing buffer, 100 μl of standard or sample were added into 
respective wells. The granzyme B standard was 1:2 serially diluted with concentrations 
ranging from 10.3 pg/ml to 1,300 pg/ml, and the perforin standard 1:2 dilutions ranged from 
31.25 pg/ml to 4,000 pg/ml. Plates were incubated at room temperature for two hours and 
washed three times with washing buffer. For granzyme B and perforin detection, 100 μl of 
0.5 μg/ml GB11-biotin and 1 μg/ml Pf-344-biotin, respectively, were added to each well and 
incubated at room temperature for one hour. After plates were washed three times with 
Material and Methods 
 
29 
 
washing buffer, 100 μl/well Streptavidin-HRP (1:1,000 in assay diluent) were added for one 
hour at room temperature. Plates were washed three times with washing buffer and 75 μl 
of TMB substrate solution were added to each well. The reaction was stopped using 
75 μl/well 2N H2SO4, and samples were then analyzed with an ELISA reader at 450 nm. 
2.2.6. Western Blot for glucosylceramide synthase (GCS) 
  For analysis of GCS-expression using Western blot, cell pellets of 5x106-1x107 cells 
were collected from SK-N-BE(1)/SK-N-BE(2), SMS-KAN/SMS-KANR, SMS-KCN/SMS-
KCNR, and CHLA-15/CHLA-20. Cell pellets were resuspended in 100 μl lysis buffer 
containing protease inhibitor cocktail (PIC, 1 μl/1x106 cells) and incubated on ice for 
15 min, followed by centrifugation at 10,000x g for 30 min. Supernatant was transferred 
into a new Eppendorf tube, and protein concentration was determined using BioRad 
protein assay. Therefore, BioRad protein assay reagent was diluted 1:5 in aqua dest and 
added into a 96-well plate at a volume of 250 μl/well. 1 μl/well standard dilutions, ranging 
from 10 mg/ml to 0.15 mg/ml BSA, or 1 μl/well of sample was added to the respective 
wells. Samples were incubated for 5 min and analyzed with an ELISA reader at a 
wavelength of 595 nm. 
  After protein concentration was determined, 40 μg of protein were diluted 1:2 with 
Leammli sample buffer containing β-mercaptoethanol, and samples were denatured at 
95°C for 5 min. SDS-PAGE was performed at 80 V for 20 min followed by 120 V for one 
hour, using a 10% resolving gel and a 4% stacking gel to resolve all proteins of the cell 
lysate. Fiber pads, filter paper and nitrocellulose membrane were incubated in transfer 
buffer for 20 min prior to blotting. The sandwich was assembled in the following order: fiber 
pad, filter paper, gel, membrane, filter paper, fiber pad. Afterwards, the blotting tank was 
filled with the sandwich, a cooling unit and transfer buffer, and blotting was then performed 
at 100 V for one hour. To block non-specific binding, the membrane was incubated with 
Rotiblock (1x solution in PBS) and shaken at room temperature for one hour. For detection 
of GCS, the membrane was incubated overnight while rotating at 4°C with mouse anti-
human GCS antibody (1:200 diluted in Rotiblock). On the following day, the membrane was 
washed three times (10 min each) with washing buffer and was incubated with a HRP-
labelled goat anti-mouse IgG antibody (1:2,000 in PBS) for one hour at room temperature. 
After washing the membrane three times (10 min each) with washing buffer, a 1:2 mixture 
of Immun-Star-HRP peroxide buffer and Immun-Star luminol/enhancer was added to the 
membrane, and the reaction was visualized using the ChemiDoc XRS™ Molecular Imager. 
The size of the detected GCS protein band (52 kDa) was determined according to a protein 
standard (SpectraTM Multicolor Broad Range Protein Ladder) on the membrane. 
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  To compare protein expression between different samples, β-actin-expression was 
analyzed as a control. Therefore, the membrane was incubated with a HRP-labelled anti-β-
actin antibody (1:30,000 in PBS) for one hour at room temperature. After washing the 
membrane three times (5 min each) with washing buffer, protein visualization was 
performed as described above. The ratio of GCS-expression in relapse cell lines to GCS 
expression in cell lines from diagnosis was determined according to the following formula: 
(intensity of GCS in relapse / intensity of GCS in diagnosis cell line) x (intensity of β-actin in 
diagnosis cell line / intensity of β-actin in relapse cell line). 
2.2.7. In vivo efficacy of NK-92-scFv(ch14.18)-zeta in a drug-resistant NB mouse 
model 
  The in vivo efficacy of NK-92-scFv(ch14.18)-zeta was analyzed in a drug-resistant NB 
xenograft mouse model. Experiments were performed in compliance with the German Law 
for Welfare of Laboratory Animals. Since CHLA-20, NK-92-scFv(ch14.18)-zeta and NK-92-
scFv(FRP5)-zeta are all human cell lines, an immunodeficient mouse model was chosen to 
ensure engraftment of subcutaneous tumors and prevent human NK cells from being 
attacked by mouse immune cells. Therefore female NSG (NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ) 
mice were obtained at an age of 6-8 weeks from Charles River laboratories (Sulzfeld, 
Germany) and maintained under specific-pathogen free conditions. Mutation of the Prkdc 
gene affects recombination of VDJ segments in immunoglobulin genes and T cell receptor 
genes. Additionally, these mice exhibit a mutation in the gene encoding for the IL-2 
receptor gamma chain. This IL-2 receptor gamma chain is important for high affinity binding 
and signaling of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Both mutations result in a mouse 
phenotype lacking mature B cells and T cells. This phenotype also displays decreased NK 
cell numbers and only very low cytotoxic activity of the remaining NK cells. 
  To determine the efficacy of NK-92-scFv(ch14.18)-zeta, mice were challenged with 
subcutaneous tumors of the drug-resistant human NB cell line CHLA-20 and subjected to 
eight peritumoral subcutaneous injections of a combination of NK cells and human 
recombinant IL-2. CHLA-20 tumor cells were harvested, washed twice in IMDM without 
supplements (300x g, 5 min, RT) and resuspended in a 1:2 mixture of PBS and Matrigel 
(BD Biosciences, Bedford, MA, USA). Matrigel is a basement membrane extract, 
generated from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. Extracellular matrix 
proteins and growth factors in matrigel promote engraftment and growth of xenografts 
[155]. Primary tumor growth of NB tumors was induced by subcutaneous injection of 1x106 
CHLA-20 into the left flank (day 0) of 28 mice. On day three after tumor cell inoculation, 
mice received the first peritumoral subcutaneous injection of 2x107 NK cells and 200 IU IL-
2 in 150 μl PBS. NK cells were washed twice in PBS prior to injection. One experimental 
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group (n=7) received a combination of NK-92-scFv(ch14.18)-zeta and IL-2. Control groups 
(n=7) were subjected to injection of PBS (“untreated”) or NK-92-scFv(FRP5)-zeta + IL-2. 
Further, an additional control group (n=7) was injected with 200 IU IL-2 only. Since the 
parental NK-92 cell line, and therefore also the genetically engineered NK cell lines NK-92-
scFv(ch14.18)-zeta and NK-92-scFv(FRP5)-zeta are IL-2 dependent, the application of IL-2 
was included into the treatment schedule to ensure survival and stable expression of the 
CAR in vivo.  
  Mice received eight injections of the combination of NK cells and IL-2 in total, starting 
on day three after tumor cell inoculation (injections on day 3, 7, 11, 15, 19, 26, 33, 40). 
Additional intraperitoneal injections of IL-2 (1000 IU/mouse) were applied the day after 
each NK cell injection (days 4, 8, 12, 16, 20, 27, 34, 41) to both NK cell-treated groups as 
well as the IL-2 control group. Untreated mice received 100 μl PBS intraperitoneally on the 
respective days. To determine the effect of NK cell applications on subcutaneous primary 
tumor growth, tumor size was measured every other day using a micro caliper and tumor 
volume was calculated according to the following formula: length x (width)2 x 0.5. Mice 
were sacrificed at a maximum tumor volume of 800 mm3 or when tumors showed signs of 
necrosis.  
2.2.8. Statistical analysis 
  Statistical analyses were done with GraphPad Prism (GraphPad Software Inc., La 
Jolla, CA, USA). An unpaired t-test was used for comparison of two experimental groups, 
while statistic analysis of more than two experimental groups was performed using a one 
way ANOVA-test. Experimental differences were considered statistically significant if the 
resulting p-value was lower than 0.05 (*p<0.05, **p<0.01, ***p<0.001). Statistical analysis 
of in vivo survival data was completed using a Log-rank (Mantel-Cox) test. To account for 
multiple comparison of survival curves, only p-values less than the Bonferroni-corrected 
significance level of 0.008 were considered significant (*p<0.008, **p<0.002, ***p<0.0002).  
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3. Results 
3.1. GD2-specificity of NK-92-scFv(ch14.18)-zeta 
3.1.1. Chimeric antigen receptor expression on NK-92-scFv(ch14.18)-zeta 
  To confirm GD2-specificity of NK-92-scFv(ch14.18)-zeta, CAR-expression was 
analyzed using flow cytometry. In this regard, two different staining strategies can be 
utilized for flow cytometric analysis of GD2-specific CAR-expression. The first is based on 
the use of an anti-idiotype antibody (anti-IdAb) called ganglidiomab, which has recently 
been generated and characterized as a surrogate of GD2. Due to its anti-idiotype 
characteristics, ganglidiomab is able to specifically bind the antigen binding regions of the 
GD2-specific CAR (Fig. 3.1.1 A). Therefore, both GD2-specificity and CAR-expression can 
be evaluated. The second staining strategy is based on an antibody recognizing a Myc-tag 
which is located in the extracellular part of the CAR (Fig. 3.1.1 B). While a positive staining 
of the Myc-tag indicates CAR-expression on NK cells, it does not provide any information 
about CAR-specificity. In addition to NK-92-scFv(ch14.18)-zeta, the control NK cell lines 
NK-92, NK-92-pLXSN as well as the ErbB2-specific NK-92-scFv(FRP5)-zeta were 
analyzed to confirm that they do not express a GD2-specific CAR (Fig. 3.1.1 C).  
  Staining of NK-92-scFv(ch14.18)-zeta using the anti-IdAb revealed that all NK-92-
scFv(ch14.18)-zeta cells homogeneously express a CAR that specifically recognizes GD2. 
Myc-tag staining also showed CAR-expression on NK-92-scFv(ch14.18)-zeta. For parental 
NK-92 cells as well as the empty vector-transduced NK-92-pLXSN cell line, neither staining 
with anti-IdAb nor Myc-tag-specific antibody showed CAR-expression on the cell surface. 
Analysis of NK-92-scFv(FRP5)-zeta revealed a high and homogeneous CAR-expression 
after staining with the Myc-tag-specific antibody. Staining with anti-IdAb did not show any 
positive signal. This shows that the control cell line NK-92-scFv(FRP5)-zeta expresses a 
CAR that is not GD2-specific. 
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Figure 3.1.1: Chimeric antigen receptor expression on NK cell lines. Chimeric antigen receptor expression 
was analyzed with flow cytometry, based on two staining strategies. (A) CAR-detection by staining with 
1 μg/1x106 cells anti-idiotype antibody ganglidiomab (red) and PE-labeled rat anti-mouse secondary antibody 
(orange). (B) CAR-detection based on recognition of the extracellular Myc-tag. NK cells were stained with 
1 μg/1x106 cells anti-Myc-tag antibody (green) and PE-labeled rat anti-mouse secondary antibody (orange).  
(C) Representative histograms of CAR-staining with both staining strategies (isotype controls: gray dashed 
curves; CAR staining: filled black curve). 
3.1.2. Cytotoxicity of NK-scFv(ch14.18)-zeta and control NK cell lines towards GD2+ 
and GD2- NB cell lines 
  Calcein release cytotoxicity assays were performed to analyze GD2-specificity and 
functionality of the CAR expressed on NK-92-scFv(ch14.18)-zeta. To determine a suitable 
ratio of effector cells to target cells (E:T ratio) for these experiments, NK-92-scFv(ch14.18)-
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zeta and the control cell line NK-92-scFv(FRP5)-zeta were applied at different E:T ratios 
(ranging from 0.8:1 to 50:1) in a calcein release cytotoxicity assay with the GD2+ NB cell 
line CHLA-20 as target cells (Fig. 3.1.2.1). This experiment showed that NK-92-
scFv(ch14.18)-zeta effectively lysed CHLA-20, compared to the control cell line NK-92-
scFv(FRP5)-zeta and further that this effect was dependent on the E:T ratio. For the 
following cytotoxicity assays an E:T ratio of 6.3:1 was chosen, since the GD2-specific effect 
was clearly visible at this ratio and the amount of NK cells needed at this E:T ratio was 
applicable for complex experimental settings. 
   
 
 
 
 
 
 
 
 
 
 
  After a suitable E:T ratio was determined, NK-92-scFv(ch14.18)-zeta as well as all 
control NK cell lines were analyzed for their specific cytotoxicity towards the GD2+ NB cell 
line CHLA-20 and the GD2- NB cell line SK-N-SH in calcein release assays. GD2-
expression of target cell lines was confirmed with flow cytometry (Fig. 3.1.2.2 A). For 
comparison of independent experiments, calcein release data were normalized using NK-
92-scFv(ch14.18)-zeta. Calcein assays revealed that specific cytotoxicities of NK-92-
scFv(ch14.18)-zeta and control NK cell lines towards the GD2-negative NB cell line SK-N-
SH at an E:T ratio of 6.3:1 were not statistically different from each other, with specific 
cytotoxicities ranging from 19% (NK-92-pLXSN) to 22% (NK-92) (Fig. 3.1.2.2 B). In 
contrast, NK-92-scFv(ch14.18)-zeta effectively lysed the GD2-expressing cell line CHLA-20 
(specific cytotoxicity 55%), compared to control NK cell lines with cytotoxicities ranging 
from 22% for NK-92 to 25% for NK-92-scFv(FRP5)-zeta. These results clearly show that 
expression of the GD2-specific CAR on NK-92-scFv(ch14.18)-zeta results in a significantly 
higher cytotoxicity towards GD2-expressing cells compared to basal cytotoxicity of control 
NK cell lines. Further, comparison of all control NK cell lines revealed that their cytotoxicity 
is comparable. Therefore, only one NK control cell line was used as control in all following 
cytotoxicity assays. 
Figure 3.1.2.1: Determination of suitable 
E:T ratio for cytotoxicity assays. Specific 
cytotoxicities of NK-92-scFv(ch14.18)-zeta  
(black curve) and the control cell line NK-92-
scFv(FRP5)-zeta (gray curve) were analyzed 
in a calcein release assay with the GD2+ NB 
cell line CHLA-20 as target cells. To 
determine a suitable E:T ratio for further 
cytotoxicity assays, different E:T ratios in the 
range of 0.8:1 to 50:1 were tested. Results 
are presented as mean specific cytotoxicity ± 
SD from three independent experiments. 
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Figure 3.1.2.2: GD2-specificity of NK-92-scFv(ch14.18)-zeta. (A) GD2-expression on target cell lines CHLA-
20 and SK-N-SH was analyzed with flow cytometry. Results are presented as one representative histogram for 
each cell line. Cells were stained with either 1 μg anti-GD2 antibody ch14.18 (filled black curve) or 1 μg isotype 
control (dashed black curve), followed by incubation with PE-labeled secondary antibody. (B) Cytotoxicity of 
NK-92-scFv(ch14.18)-zeta as well as control NK cell lines towards CHLA-20 and SK-N-SH was determined in 
calcein release assays at an E:T ratio of 6.3:1. NK-92-scFv(ch14.18)-zeta-mediated lysis of CHLA-20 was 
statistically different from lysis mediated by control NK cell lines (***p<0.001). Further, the difference in specific 
cytotoxicity of NK-92-scFv(ch14.18)-zeta towards CHLA-20 and SK-N-SH was statistically significant 
(***p<0.001). 
3.2. Cytotoxicity of NK-92-scFv(ch14.18)-zeta towards GD2-
expressing NB cell lines 
  Functionality and cytotoxic activity of NK-92-scFv(ch14.18)-zeta was further 
confirmed in 51Cr release cytotoxicity assays with a panel of six different GD2-positive NB 
cell lines (CHLA-136, CHLA-79, CHLA-20, SK-N-BE(2), LA-N-1, LA-N-5), some of which 
exhibit partial or multidrug resistance. GD2-expression of all NB cell lines was confirmed by 
flow cytometry and results are shown in figure 3.2 A. To demonstrate GD2-specific lysis 
mediated by NK-92-scFv(ch14.18)-zeta, lysis mediated by control NK cells was set to zero 
as baseline level, and NK-92-scFv(ch14.18)-zeta-mediated lysis was normalized against 
lysis by control NK cell lines. Therefore, specific cytotoxicities presented in Figure 3.2 B 
represent the difference in specific lysis between the control NK cell line and NK-92-
scFv(ch14.18)-zeta expressing the GD2-specific CAR.  
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  51Cr release assays revealed that NK-92-scFv(ch14.18)-zeta, at an E:T ratio of 6.3:1, 
effectively lysed all tested GD2-expressing NB cell lines, with specific cytotoxicities ranging 
from 34% (CHLA-79) to 66% (CHLA-136) (Fig. 3.2 B). For LA-N-5, CHLA-136, CHLA-79 
and SK-N-BE(2), the empty vector control cell line NK-92-pLXSN was used as control, 
while parental NK-92 cells were utilized as control for the 51Cr release assays with CHLA-
20 and LA-N-1. These results show that GD2-specific CAR expression enables NK-92-
scFv(ch14.18)-zeta to effectively lyse GD2-expressing NB cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2-positive NB cell lines. (A) GD2-expression 
on six NB cell lines was analyzed using flow cytometry. Cells were stained with either 1 μg anti-GD2 antibody 
ch14.18 (filled curve) or 1 μg isotype control (dashed curve), followed by incubation with PE-labeled secondary 
antibody. Results are shown as one representative histogram for each cell line. (B) Cytotoxicity of NK-92-
scFv(ch14.18)-zeta towards six GD2-positive NB cell lines at an E:T ratio of 6.3:1 was analyzed using 51Cr-
release assays. Specific cytotoxicity of NK-92-scFv(ch14.18)-zeta-mediated lysis was normalized against lysis 
by control NK cell lines. Results are presented as mean specific cytotoxicity ± SD from at least three 
independent experiments. 
3.3. Role of GD2 recognition by chimeric antigen receptor for 
activation of NK-92-scFv(ch14.18)-zeta 
  To determine whether NK-92-scFv(ch14.18)-zeta-mediated cytotoxicity is dependent 
on recognition of the target antigen GD2, the CAR was blocked using the anti-IdAb 
ganglidiomab that specifically binds and blocks the antigen binding regions of the CAR. 
51Cr release assays were performed using the GD2+ NB cell lines LA-N-1 (Fig. 3.3.1 A) and 
LA-N-5 (Fig. 3.3.1 B) as target cells. Data from independent experiments were normalized 
against specific cytotoxicity of control samples without addition of any antibody to compare 
the effect of CAR-blocking on NK-92-scFv(ch14.18)-zeta-mediated lysis. In the case of LA-
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N-1, addition of anti-IdAb significantly decreased specific cytotoxicity from 36% without 
addition of antibody to 8% with 10 μg/ml anti-IdAb. In contrast, addition of 10 μg/ml mouse 
IgG1 as isotype control did not result in decreased specific cytotoxicity. These observations 
were confirmed with LA-N-5 as target cells, resulting in a significant decrease in specific 
cytotoxicity from 49% in controls to 13% after addition of 10 μg/ml anti-IdAb. Addition of the 
same amounts of mouse IgG1 did not have a significant effect on specific cytotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1: Blocking of the CAR expressed on NK-92-scFv(ch14.18)-zeta. GD2-specific CAR and thereby 
NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2-positive NB cell lines LA-N-1 (A) and LA-N-5 (B) was blocked 
in a 51Cr-release assay by addition of 10 μg/ml anti-IdAb. For controls, respective amounts of mouse IgG1 were 
applied. Results are presented as mean specific cytotoxicity in % ± SD from at least three independent 
experiments. Data of independent experiments were normalized using specific cytotoxicity of control samples. 
Abrogation of NK-92-scFv(ch14.18)-zeta-mediated lysis of LA-N-1 and LA-N-5 by addition of anti-IdAb was 
statistically significant (***p< 0.001). 
 
  These results were further confirmed by CAR-blocking in calcein release cytotoxicity 
assays using the GD2+ NB cell lines CHLA-15 and CHLA-20 as well as the GD2- 
erythroleukemia cell line K562 as target cells (Fig. 3.3.2). For comparison of independent 
experiments, calcein release data were normalized using control samples without addition 
of antibodies. These assays revealed that NK-92-scFv(ch14.18)-zeta-mediated lysis of 
GD2-expressing CHLA-15 was almost completely abrogated by addition of 10 μg/ml anti-
IdAb (38% specific cytotoxicity in controls compared to 6% with anti-IdAb), while addition of 
the same amounts of isotype control did not have any effect (Fig. 3.3.3 A). CAR-blocking 
by addition of anti-IdAb also induced almost complete abrogation of NK-92-scFv(ch14.18)-
zeta-mediated lysis of GD2+ CHLA-20 (11% specific cytotoxicity with anti-IdAb compared to 
40% specific cytotoxicity in controls). Addition of the same amounts of isotype control did 
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not have any effect (Fig. 3.3.3 B). In contrast, lysis of GD2-negative K562 was unaffected 
by addition of CAR-blocking anti-IdAb (37% specific cytotoxicity in controls compared to 
36% with anti-IdAb and 37% with isotype control) (Fig. 3.3.3 C), indicating that this lysis is 
mediated by GD2-independent mechanisms. 
    
 
 
 
 
 
 
 
 
Figure 3.3.2: GD2 expression on NB cell lines CHLA-15 and CHLA-20 and erythroleukemia cell line 
K562. For flow cytometric analysis of GD2-expression, cells were stained with either 1 μg anti-GD2 antibody 
ch14.18 (filled curve) or 1 μg isotype control (dashed curve), followed by incubation with PE-labeled secondary 
antibody. Results are shown as one representative histogram for each cell line. 
 
  These experiments demonstrate that NK-92-scFv(ch14.18)-zeta-mediated lysis of 
GD2-expressing cell lines is based on recognition of GD2 by the GD2-specific CAR, 
expressed on the NK cell line. The almost complete abrogation of specific cytotoxicity of 
NK-92-scFv(ch14.18)-zeta towards GD2+ cell lines after blocking the CAR further indicates 
that GD2-induced activation is the primary mechanism of target cell recognition and 
thereby NK-92-scFv(ch14.18)-zeta-mediated lysis.  
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Figure 3.3.3: Effect of CAR-blocking on NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2+ and GD2- 
target cell lines. CAR was blocked using 10 μg/ml anti-IdAb in a calcein release assay. Results are presented 
as mean specific cytotoxicity in % ± SD of at least three independent experiments. Data of independent 
experiments were normalized using specific cytotoxicity of control samples. (A) NK-92-scFv(ch14.18)-zeta-
mediated lysis of GD2+ NB cell line CHLA-15 was abrogated by addition of 10 μg/ml anti-IdAb. This effect was 
statistically significant (***p<0.001). (B) Abrogation of NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2+ NB 
cell line CHLA-20 by addition of 10 μg/ml anti-IdAb was statistically significant (***p<0.001). (C) CAR-blocking 
did not have any effect on NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2- cell line K562. 
 
  An alternative approach of disrupting the interaction of the target antigen GD2 on 
tumor cells and the CAR expressed on NK-92-scFv(ch14.18)-zeta is blocking the target 
antigen GD2 by addition of the GD2-specific antibody ch14.18. Importantly, NK-92 cells 
lack expression of FcγRs, and therefore addition of ch14.18 does not induce ADCC 
towards target cells. Ch14.18 was added during co-incubation of NK-92-scFv(ch14.18)-
zeta and target cells in a calcein release cytotoxicity assay to further confirm that NK-92-
scFv(ch14.18)-zeta-mediated lysis is dependent on recognition of GD2 (Fig. 3.3.4). CHLA-
15 and CHLA-20 were used as GD2+ NB cell lines target cells in these assays. Again, the 
erythroleukemia cell line K562 was utilized as negative control. Addition of 10 μg/ml 
ch14.18 during co-incubation resulted in abrogation of NK-92-scFv(ch14.18)-zeta-mediated 
lysis of CHLA-15 (13% specific cytotoxicity compared to 38% specific lysis in control 
without antibody) (Fig. 3.3.4 A). Addition of same amounts of rituximab as control did not 
have any effect. Comparable results were obtained with CHLA-20 as target cells (Fig. 3.3.4 
B). Specific cytotoxicity of NK-92-scFv(ch14.18)-zeta was abrogated by addition of 
10 μg/ml ch14.18 (14% specific cytotoxicity) compared to controls without addition of 
antibody (54% specific cytotoxicity) or addition of 10 μg/ml rituximab (57% specific 
cytotoxicity). In contrast, lysis of the negative control K562 was unaffected by addition of 
ch14.18 and thereby comparable in all samples (51% specific cytotoxicity in controls, 52% 
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and 54% specific lysis after addition of 10 μg/ml ch14.18 and same amounts of rituximab, 
respectively) (Fig. 3.3.4 C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4: Effect of GD2-blocking on NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2+ and GD2- 
target cell lines. GD2 on target cells was blocked using 10 μg/ml ch14.18 in a calcein release assay. Results 
are presented as mean specific cytotoxicity in % ± SD of three independent experiments. Data of independent 
experiments were normalized using specific cytotoxicity of control samples. (A) NK-92-scFv(ch14.18)-zeta-
mediated lysis of GD2+ NB cell line CHLA-15 was abrogated by addition of 10 μg/ml ch14.18. This effect was 
statistically significant (***p<0.001). (B) Addition of 10 μg/ml ch14.18 resulted in abrogation of NK-92-
scFv(ch14.18)-zeta-mediated lysis of GD2+ NB cell line CHLA-20. This effect was statistically significant 
(***p<0.001). (C) GD2-blocking did not have any effect on NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2- 
cell line K562. 
  
  Additionally, the impact of GD2 recognition by the CAR on activation of NK-92-
scFv(ch14.18)-zeta was assessed using immobilized GD2. NK-92-scFv(ch14.18)-zeta were 
incubated with either immobilized target antigen GD2, or the ganglioside GM2 as a 
negative control. Activation of NK-92-scFv(ch14.18)-zeta was confirmed by measuring the 
concentration of effector molecules granzyme B (Fig. 3.3.5 A) and perforin (Fig. 3.3.5 B) in 
the supernatant, using ELISA. This experimental design excludes all possible stimuli that 
might be present on a target cell and potentially induce activation of NK-92-scFv(ch14.18)-
zeta, such as activating NK cell ligands. Therefore, this assay provides a possibility to 
analyze the effect of GD2 on the activation of NK-92-scFv(ch14.18)-zeta. Incubation with 
immobilized GD2 resulted in a significant 6-fold increase in granzyme B and a 2.5-fold 
increase in perforin release, compared to NK-92-scFv(ch14.18)-zeta controls. In contrast, 
incubation with GM2 did not have a significant effect on granzyme B or perforin release of 
NK-92-scFv(ch14.18)-zeta. This confirms GD2-specificity of NK-92-scFv(ch14.18)-zeta and 
shows that GD2 as a stimulus is sufficient to induce activation of CAR-expressing NK-92-
scFv(ch14.18)-zeta. 
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Figure 3.3.5: Release of effector molecules granzyme B and perforin in response to immobilized 
gangliosides. NK-92-scFv(ch14.18)-zeta were incubated with 100 ng GD2 or GM2 for five hours and effector 
molecules granzyme B (A) and perforin (B) were quantified in supernatants using ELISA. Results are presented 
as mean effector molecule concentration in ng/ml ± SD from three independent experiments. Data of 
independent experiments were normalized according to NK-92-scFv(ch14.18)-zeta that were incubated without 
immobilized gangliosides (control). Differences in granzyme B and perforin release in response to incubation 
with immobilized GD2 were statistically significant (***p<0.001). 
  
  To show that the GD2-induced increase in effector molecule release of NK-92-
scFv(ch14.18)-zeta is dependent on GD2 recognition by the CAR, the receptor was 
blocked by addition of 10 μg/ml anti-IdAb in the presence of immobilized GD2. 
Concentrations of effector molecules in supernatants were then determined using ELISA. 
The 2.4-fold increase in granzyme B release in the presence of immobilized GD2, 
compared to NK-92-scFv(ch14.18)-zeta incubated in the absence of gangliosides (control), 
could be completely abrogated by addition of anti-IdAb (3.3.6 A and B). Addition of 
10 μg/ml IgG1 isotype control in the presence of immobilized GD2 still resulted in a 2.4-fold 
increase. Furthermore, incubation of control NK cell line NK-92-pLXSN in the presence of 
GD2 had no effect on granzyme B release, while both NK cell lines reacted to non-specific 
activation with PMA/Ionomycin (5.3-fold increase in NK-92-scFv(ch14.18)-zeta and 4.6-fold 
increase in NK-92-pLXSN) (Fig. 3.3.6 B). Analysis of perforin release of NK-92-
scFv(ch14.18)-zeta revealed similar results (Fig. 3.3.6 C and D). Incubation of NK-92-
scFv(ch14.18)-zeta in the presence of immobilized GD2 resulted in a 1.6-fold increase in 
perforin release compared to NK-92-scFv(ch14.18)-zeta incubated in the absence of GD2. 
This GD2-induced increase could be abrogated by addition of anti-IdAb, in contrast to 
addition of isotype control (1.7-fold increase in perforin production). Again, NK-92-pLXSN 
did not respond to activation with GD2, while both NK cell lines reacted to non-specific 
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activation with PMA/Ionomycin (2.2-fold increase in NK-92-scFv(ch14.18)-zeta and 3.8-fold 
increase in NK-92-pLXSN) (Fig. 3.3.6 D). 
  These results show that the expression of the GD2-specific CAR enables NK-92-
scFv(ch14.18)-zeta to specifically respond to activation with GD2 in contrast to the control 
NK cell line NK-92-pLXSN. Furthermore, results demonstrate that stimulation with the 
target antigen GD2 is sufficient to induce activation of NK-92-scFv(ch14.18)-zeta, thereby 
suggesting an antigen-specific stimulation as the primary mechanism of activation of NK-
92-scFv(ch14.18)-zeta, in the absence of other possible activating stimuli that might be 
present on a target cell. 
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Figure 3.3.6: Effect of CAR-blocking on release of effector molecules granzyme B and perforin. NK-92-
scFv(ch14.18)-zeta and the NK control cell line NK-92-pLXSN were incubated in the presence or absence of 
100 ng GD2 for five hours and the concentration of effector molecules granzyme B and perforin was 
determined in supernatant using ELISA. To determine the effect of blocking the GD2-specific CAR, 10 μg/ml 
anti-IdAb or respective amounts of mouse IgG1 as isotype control were added during incubation. As a control, 
PMA/Ionomycin was used for non-specific activation of NK cells. To compare independent experiments, data 
were normalized according to basal release of effector molecules in the absence of GD2. (A) Mean granzyme B 
release of NK-92-scFv(ch14.18)-zeta in ng/ml ± SD of three independent experiments. Changes in granzyme B 
release in response to stimulation with GD2 as well as abrogation of granzyme B release by addition of anti-
IdAb were statistically significant (***p<0.001). (B) Fold increase in granzyme B production of NK-92-
scFv(ch14.18)-zeta and NK-92-pLXSN compared to respective controls incubated in the absence of GD2. 
Results are presented as mean fold increase ± SD of three independent experiments. (C) Mean perforin 
release of NK-92-scFv(ch14.18)-zeta in ng/ml ± SD of three independent experiments. Increase in perforin 
production in response to stimulation with GD2 as well as abrogation of perforin release by addition of anti-IdAb 
were statistically significant (***p<0.001). (D) Fold increase in perforin production of NK-92-scFv(ch14.18)-zeta 
and NK-92-pLXSN compared to respective controls incubated in the absence of GD2. Results are presented as 
mean fold increase ± SD of three independent experiments. 
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  The impact of GD2 antigen recognition on NK-92-scFv(ch14.18)-zeta-mediated lysis 
was further directly analyzed by blocking ganglioside synthesis. Therefore, two GD2-
expressing cell lines (SK-N-BE(2), CHLA-20) were treated with the selective 
glucosylceramide synthase (GCS) inhibitor PPPP (1-phenyl-2-hexadecanoylamino-3-
pyrollidino-1-propanol). Glucosylceramide synthase is the first enzyme in ganglioside 
synthesis and mediates the conversion of ceramides to glucosylceramides. The effect of 
GCS-inhibition on GD2-expression was confirmed using flow cytometry. Figure 3.3.7 A 
shows representative histograms of GD2 expression on PPPP- as well as vehicle-treated 
SK-N-BE(2) and CHLA-20 and the respective mean fluorescence intensities (MFI). To 
compare GD2-expression levels between independent experiments, the mean 
fluorescence intensity ratios (MFI-ratio) were calculated according to the following formula: 
mean fluorescence intensity of GD2-stained sample / mean fluorescence intensity of 
isotype control. Results of five independent experiments are presented in Figure 3.3.7 B as 
the mean MFI ratio ± SD for PPPP- and vehicle-treated SK-N-BE(2) and CHLA-20, 
demonstrating that GCS-inhibition results in significantly reduced GD2 surface expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.7: Effect of GCS-inhibition on GD2 surface expression of NB cell lines. SK-N-BE(2) and CHLA-
20 were treated with 1 μM PPPP or the same volume of 100% ethanol (vehicle control) for 48 h and GD2 
expression was analyzed with flow cytometry. (A) Representative histograms of GD2-expression on PPPP- 
(dashed black curve) and vehicle-treated (filled black curve) SK-N-BE(2) and CHLA-20. Controls were stained 
with rituximab as isotype control (black curve). (B) MFI ratios of GD2-expression on PPPP- and vehicle-treated 
SK-N-BE(2) and CHLA-20. MFI ratio was calculated according to the formula: mean fluorescence intensity of 
GD2-stained sample divided by mean fluorescence intensity of isotype control. PPPP-treatment resulted in 
significantly decreased GD2 surface expression on SK-N-BE(2) (**p=0.0037) and CHLA-20 (*p=0.01), 
compared to vehicle-treated cells. Results are presented as mean MFI ratio ± SD of five independent 
experiments. 
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  Furthermore, application of PPPP- and vehicle-treated SK-N-BE(2) and CHLA-20 
target cells in a 51Cr release assay revealed that decreased GD2 surface expression 
correlated with decreased sensitivity of PPPP-treated SK-N-BE(2) and CHLA-20 towards 
NK-92-scFv(ch14.18)-zeta-mediated lysis (14% and 38% specific cytotoxicity, 
respectively), compared to vehicle-treated cells (39% and 63% specific cytotoxicity, 
respectively) (Fig. 3.3.8). 
 
Figure 3.3.8: Effect of GCS-inhibition on NK-92-
scFv(ch14.18)-zeta-mediated lysis of GD2+ NB 
cell lines. SK-N-BE(2) and CHLA-20 were treated 
with 1 μM PPPP or the same volume of 100% 
ethanol (vehicle control) for 48 h. Sensitivity 
towards NK-92-scFv(ch14.18)-zeta-mediated lysis 
was analyzed in a 51Cr release assay. PPPP-
treatment of SK-N-BE(2) and CHLA-20 resulted in 
significantly reduced sensitivity towards NK-92-
scFv(ch14.18)-mediated cytotoxicity (***p<0.001). 
Results are presented as mean specific cytotoxicity 
in % ± SD of three independent experiments. To 
compare independent experiments, data were 
normalized to respective vehicle-treated control. 
3.4. Sensitivity of NB relapse cell lines towards NK-92-
scFv(ch14.18)-zeta-mediated lysis 
  Despite the use of intensive multi-modal therapy protocols, prognosis for high-risk NB 
patients remains poor. The treatment of high-risk NB patients is particularly challenging, 
because many patients initially respond to therapy but develop progressive disease or 
relapse, which is potentially caused by minimal residual disease. Unfortunately, relapsed 
tumors often exhibit drug resistance and are refractory towards chemotherapy. Therefore, 
alternative approaches for treatment of minimal residual disease are needed. 
  To address this problem, the sensitivity of NB cell line pairs from four patients 
towards NK-92-scFv(ch14.18)-zeta-mediated lysis was analyzed in 51Cr release assays. 
Each cell line pair consists of one cell line established at time of diagnosis (SK-N-BE(1), 
SMS-KAN, SMS-KCN, CHLA-15) and a corresponding cell line generated from relapse 
material (SK-N-BE(2), SMS-KANR, SMS-KCNR, CHLA-20) of the same patient. For 
comparison of independent experiments, specific cytotoxicity of control NK cell lines was 
set to zero and specific cytotoxicity of NK-scFv(ch14.18)-zeta was normalized against 
control NK cell lines. 
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  51Cr release assays revealed that relapse cell lines of all patients tested are still 
sensitive towards NK-92-scFv(ch14.18)-zeta-mediated lysis, with specific cytotoxicities 
ranging from 32% (SMS-KANR) to 47% (SK-N-BE(2) (Fig. 3.4.1). Interestingly, in three out 
of four tested cell line pairs (SK-N-BE(1)/(2), SMS-KAN/SMS-KANR, SMS-KCN/SMS-
KCNR), the relapse cell line showed significantly higher sensitivity towards NK-92-
scFv(ch14.18)-zeta compared to the respective cell line from time point of diagnosis. 
Relapse cell line SK-N-BE(2) exhibited a 2-fold higher sensitivity compared to SK-N-BE(1). 
Sensitivity of SMS-KANR towards NK-92-scFv(ch14.18)-zeta was about 1.9-fold higher 
than sensitivity of SMS-KAN. In case of SMS-KCN/SMS-KCNR, the relapse cell line SMS-
KCNR showed an almost 1.5 fold higher sensitivity. The fourth patient cell line pair (CHLA-
15/CHLA-20) exhibited comparable sensitivities towards NK-92-scFv(ch14.18)-zeta. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1: Sensitivity of NB cell line pairs towards NK-92-scFv(ch14.18)-zeta-mediated lysis. NB cell 
line pairs of four patients were analyzed in 51Cr release assays. NK-92-scFv(ch14.18)-zeta effectively lysed all 
relapse cell lines at an E:T ratio of 6.3:1. In three out of four patients tested (SK-N-BE(1)/(2), SMS-KAN/SMS-
KANR, SMS-KCN/SMS-KCNR), the relapse cell line exhibited a significantly higher sensitivity towards NK-92-
scFv(ch14.18)-mediated lysis (***p≤0.001), compared to the respective cell line from time point of diagnosis.  
Specific cytotoxicity of control cell lines was set to zero and NK-92-scFv(ch14.18)-zeta-mediated lysis was 
normalized against control NK cells. Results are presented as mean specific cytotoxicity in % ± SD of at least 
three independent experiments.  
 
  Since recognition of GD2 by the CAR was shown to be the main mechanism of NK-
92-scFv(ch14.18)-zeta-mediated lysis of GD2-positive NB cell lines, cell line pairs from all 
four patients were analyzed for GD2 surface expression. Figure 3.4.2 A displays 
representative histograms of GD2-expression on NB cell line pairs. To compare GD2 
expression levels of independent experiments, mean fluorescence intensity ratios (MFI-
ratio) were calculated according to the following formula: MFI of GD2-stained sample 
divided by MFI of isotype-stained sample. Results of four independent experiments are 
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presented in Figure 3.4.2 B as the mean MFI ratio ± SD. Flow cytometric analysis of GD2 
surface expression revealed that, in three out of four cases tested, the relapse cell line 
exhibited significantly higher GD2-expression compared to the respective cell line from 
time point of diagnosis. In the case of CHLA-15/CHLA-20, GD2-expression on the relapse 
cell line was not significantly higher. Thus, higher GD2-expression in relapse cell lines SK-
N-BE(2), SMS-KANR and SMS-KCNR correlated with increased sensitivity of these cell 
lines towards NK-92-scFv(ch14.18)-zeta-mediated lysis in 51Cr release assays.  
 These results show that relapse cell lines are sensitive towards NK-92-scFv(ch14.18)-
zeta-mediated lysis, because they still express the antigen GD2. In our tests, the majority 
of relapse cell lines even displayed significantly increased GD2-expression, correlating with 
an increased specific cytotoxicity mediated by NK-92-scFv(ch14.18)-zeta. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2: GD2-expression on NB cell line pairs. GD2-expression on NB cell line pairs of four patients 
was determined with flow cytometry. (A) Representative histograms for each cell line pair. (gray dashed curve: 
isotype control of diagnosis cell line; gray solid curve: GD2-staining of diagnosis cell line; black dashed curve: 
isotype control of relapse cell line; filled black curve: GD2-staining of relapse cell line). (B) MFI ratios of GD2-
expression NB cell line pairs. MFI ratio was calculated according to the formula: mean fluorescence intensity of 
GD2-stained sample divided by mean fluorescence intensity of isotype control. Relapse cell lines SK-N-BE(2), 
SMS-KANR and SMS-KCNR exhibited a significantly higher GD2-expression than respective diagnosis cell 
lines (*p<0.05). Results are presented as mean MFI ratio ± SD of four independent experiments. 
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  Increased expression of GCS is associated with relapse cell lines and a common 
mechanism of drug resistance that is activated in tumor cells to avoid accumulation of 
ceramides and evade apoptosis [156-158]. Since GCS as the first enzyme in GD2 
synthesis was shown to have an effect on GD2 surface expression and thereby on NK-92-
scFv(ch14.18)-zeta-mediated lysis (Fig. 3.3.6 and 3.3.7), GCS-expression in NB cell line 
pairs was analyzed using Western blot. All relapse cell lines showed a higher GCS-
expression compared to their respective diagnosis cell lines (Fig. 3.4.3 A). Based on the β-
actin control, GCS-expression was normalized for all cell lines and the ratio of GCS 
expression relapse/diagnosis cell line was calculated. To compare results from 
independent experiments for each cell line pair, mean ratios were calculated (Fig. 3.4.3 B). 
Results showed that the relapse cell lines SMS-KANR, SMS-KCNR and SK-N-BE(2) 
exhibited higher GCS-expression, while expression in the relapse cell line CHLA-20 was 
only slightly increased compared to diagnosis cell line CHLA-15. These results correlate 
with GD2-expression on NB cell line pairs, suggesting that increased GCS-expression 
might be one possible explanation for higher sensitivity of relapse cell lines SMS-KANR, 
SMS-KCNR and SK-N-BE(2) towards NK-92-scFv(ch14.18)-zeta. 
 
 
 
 
 
 
 
 
Figure 3.4.3: GCS-expression in NB cell line pairs. GCS-expression in NB cell line pairs of four patients was 
analyzed using Western blot. For relative quantification of GCS-expression, β-actin-expression was analyzed 
as control. (A) Representative Western blots for GCS-expression (top row) as well as β-actin control (bottom 
row) in NB cell line pairs. (B) Ratio of GCS-expression of relapse to diagnosis cell lines. To compare GCS-
expression in relapse and diagnosis cell lines, GCS-expression was normalized using the respective β-actin 
control, and intensity of relapse cell line was divided by intensity of diagnosis cell line. Results are presented as 
mean ratio of GCS-expression relapse to diagnosis cell lines ± SD from at least three independent experiments.  
3.5. In vivo efficacy of NK-92-scFv(ch14.18)-zeta in a drug-resistant 
NB mouse model 
  Since NK-92-scFv(ch14.18)-zeta was effective towards a panel of GD2+ NB cell lines 
in vitro, the in vivo efficacy of a therapeutic application of NK-92-scFv(ch14.18)-zeta was 
analyzed in a drug-resistant NB xenograft mouse model.  
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  Prior to the actual in vivo study, the effect of IL-2 starvation on CAR-expression was 
examined in an in vitro experiment to determine whether an application of IL-2 should be 
included in the in vivo experiment. Therefore, NK-92-scFv(ch14.18)-zeta were cultured 
under different conditions, containing culture in complete medium, starvation from IL-2 for 
four days and culture in the absence of IL-2 for four days and subsequent transfer to 
complete medium for two additional days. CAR-expression was then analyzed in all 
samples with flow cytometry (Fig. 3.5.1). This analysis revealed that starvation from IL-2 
resulted in decreased CAR-expression compared to controls cultured in complete medium. 
Abrogated CAR-expression was reversed by culture of cells in complete medium for two 
additional days. This suggests that an application of IL-2 should be included in the 
experimental setting of the following in vivo study.  
  
 
 
 
 
 
 
 
 
 
 
 
   
   
  Therapeutic efficacy of NK-92-scFv(ch14.18)-zeta was then determined according to 
their effect on the subcutaneous primary tumor growth of GD2+ CHLA-20 tumors (Fig. 
3.5.2). The primary tumor was induced by subcutaneous injection of 1x106 CHLA-20 NB 
cells into the left flank of female NSG mice (day 0). Starting on day three after tumor 
inoculation, mice were subjected to a total of eight peritumoral injections of NK-92-
scFv(ch14.18)-zeta and 200 IU of recombinant human IL-2 (injections on day 3, 7, 11, 15, 
19, 26, 33, 40). Additionally, mice received 1000 IU of IL-2 intraperitoneally 24 h after each 
NK cell injection (injections on day 4, 8, 12, 16, 20, 27, 34, 41).  To specifically show that 
the mediated effect of a repeated application of NK-92-scFv(ch14.18)-zeta is based on the 
expression of the GD2-specific CAR on these cells, the experimental setting also included 
control groups treated with PBS only (untreated) or either IL-2 only or a combination of  the 
control NK cell line NK-92-scFv(FRP5)-zeta and IL-2. Since NK-92-scFv(ch14.18)-zeta and 
Figure 3.5.1: Impact of IL-2-starvation on 
CAR-expression on NK-92-scFv(ch14.18)-
zeta. To assess the impact of IL-2 on CAR- 
expression, NK-92-scFv(ch14.18)-zeta were 
cultured under different culture conditions 
and CAR-expression was analyzed by 
staining with the anti-IdAb ganglidiomab. 
Mouse IgG1 was used as isotype control 
(gray curve) for staining. Cells were cultured 
in either complete medium (dashed gray 
curve), IL-2-free medium for four days (black 
filled curve), or IL-2-free medium for four 
days followed by two additional days in 
complete medium (black curve). Results are 
presented as a representative histogram. 
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NK-92-scFv(FRP5)-zeta are IL-2-dependent cell lines and IL-2-dependency of CAR- 
expression had been demonstrated in a previous in vitro experiment, the application of IL-2 
was included in the treatment schedule to ensure survival and stable CAR-expression of 
NK cell lines. 
 
 
 
 
 
 
 
 
Figure 3.5.2: Treatment schedule for therapeutic treatment with NK-92-scFv(ch14.18)-zeta. 1x106 CHLA-
20 were subcutaneously injected into the left flank of female NSG (NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ) mice.  Mice 
received eight peritumoral subcutaneous (s.c.) injections of 2x107 NK cells and 200 IU human recombinant IL-2 
in total, starting on day three after tumor cell inoculation (days 3, 7, 11, 15, 19, 26, 33, 40). Additionally, mice 
were subjected to intraperitoneal (i.p.) injections of 1000 IU IL-2 24 h after each NK cell injection (days 4, 8, 12, 
16, 20, 27, 34, 41). Experimental groups (n=7) included mice treated with PBS only (untreated), IL-2 only, NK-
92-scFv(ch14.18)-zeta + IL-2 as well as a control group treated with NK-92-scFv(FRP5)-zeta + IL-2. 
 
Peritumoral injections of NK-92-scFv(ch14.18)-zeta resulted in delayed appearance of 
palpable tumors in treated mice (mean time to appearance 30 days) compared to control 
groups (mean time to appearance 13-20 days). Although growth of primary CHLA-20 
tumors was quite aggressive, treatment with GD2-specific NK-92-scFv(ch14.18)-zeta 
effectively delayed tumor growth. To demonstrate this effect, experimental groups were 
compared based on time until the tumors reached a volume of ≥150 mm3 (Fig. 3.5.3).  This 
comparison revealed that tumor growth was significantly delayed in NK-92-scFv(ch14.18)-
zeta-treated mice (49 days) compared to control groups (27-29 days). 
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Since tumor growth in control groups was comparable, Figure 3.5.4 shows tumor growth of 
individual mice in the NK-92-scFv(FRP5)-zeta control and NK-92-scFv(ch14.18)-zeta-
treated groups as well as the treatment schedule. Interestingly, the overlay of tumor growth 
of individual mice of both groups showed that mice in the NK-92-scFv(ch14.18)-zeta group 
were sacrificed at a smaller tumor size than NK-92-scFv(FRP5)-zeta-treated mice. To 
confirm this finding, the mean tumor volumes on the day mice were sacrificed of all groups 
were compared. This comparison revealed that NK-92-scFv(ch14.18)-zeta-treated mice 
were sacrificed at a lower tumor volume (348 ± 124 mm3) than control mice (untreated 
group 605 ± 101 mm3, IL-2 group 635 ± 128 mm3, NK-92-scFv(FRP5)-zeta group 666 ± 86 
mm3). Mice of the NK-92-scFv(ch14.18)-zeta-treated group had to be sacrificed before they 
reached the maximum tumor size of 800 mm3 due to development of necrosis in these 
tumors at a lower tumor volume compared to tumors in control groups. This might be a sign 
for increased tumor tissue destruction potentially caused by an increased invasion and 
killing of tumor cells by NK-92-scFv(ch14.18)-zeta. 
 
 
 
 
 
 
 
 
Figure 3.5.3: Comparison of tumor growth 
based on time to tumor volume ≥ 150 mm3.  
Tumor growth was followed up by micro-caliper 
measurements and tumor volume was 
calculated according to the formula: length x 
(width)2 x 0.5. Results are presented as mean 
time in days until an established tumor with a 
volume of ≥ 150 mm3 was developed ± SD 
(n=7). Time until the tumors reached a volume ≥ 
150 mm3 was statistically longer in NK-92-
scFv(ch14.18)-zeta-treated mice (***p<0.001). 
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Figure 3.5.4: Tumor growth of individual mice of NK-92-scFv(ch14.18)-zeta-treated group and NK-92-
scFv(FRP5)-zeta control group. Mice were challenged with subcutaneous injection of 1x106 CHLA-20 in the 
left flank (day 0). Starting on day three, mice received peritumoral subcutaneous injections of either a 
combination of 2x107 NK-92-scFv(ch14.18)-zeta and 200 IU IL-2 or 2x107 NK-92-scFv(FRP5)-zeta and 200 IU 
IL-2 (days 3, 7, 11, 15, 19, 26, 33, 40). Additional intraperitoneal injections of 1000 IU IL-2 were performed 24 h 
after each NK cell injection (days 4, 8, 12, 16, 20, 27, 34, 41). Tumor volume was calculated according to the 
formula: length x (width)2 x 0.5. Results are presented as the tumor volume of individual mice (n=7) of the NK-
92-scFv(ch14.18)-zeta-treated group (black solid curves) and the NK-92-scFv(FRP5)-zeta control group (black 
dashed curves). 
   
Most importantly, survival analysis of all groups showed, that the repeated therapeutic 
application of NK-92-scFv(ch14.18)-zeta resulted in significantly higher median survival (52 
days) compared to controls (untreated mice 30 days, IL-2 control 30 days, NK-92-
scFv(FRP5)-zeta group 32 days) (Fig. 3.5.5).  
 
 
 
 
 
 
 
 
 
 
tu
m
or
vo
lu
m
e 
in
 m
m
3
NK-92-scFv(ch14.18)-zNK-92-scFv(FRP5)-z
days after tumor cell inoculation
tumor cells s.c.
3d 7d 11d 15d 19d 26d 33d 40d
4d 8d 12d 16d 20d 27d 34d 41d
peritumoral injection of 
NK cells/IL-2 s.c.
injection of IL-2 i.p.0d
0
200
400
600
800
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
Results 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.5: Therapeutic effect of repeated peritumoral NK cell applications on survival. Primary tumors 
were induced by subcutaneous injection of 1x106 CHLA-20 into the left flank of mice (day 0). Starting on day 
three, mice received a total of eight injections of 2x107 NK-92-scFv(ch14.18)-zeta + 200 IU IL-2 (days 3, 7, 11, 
15, 19, 26, 33, 40). Additionally, mice were subjected to intraperitoneal injections of 1000 IU IL-2 24 h after 
each NK cell injection (days 4, 8, 12, 16, 20, 27, 34, 41).  Controls were injected with PBS only (untreated), IL-2 
only or NK-92-scFv(FRP5)-z and IL-2. Results are presented as percent survival (n=7) of untreated mice (gray 
dashed curve), IL-2-treated mice (gray solid curve), mice of the NK-92-scFv(ch14.18)-zeta group (black solid 
curve) and mice of the NK-92-scFv(FRP5)-zeta group (black dashed curve). Survival of NK-92-scFv(ch14.18)-
zeta-treated mice was significantly higher compared to untreated mice (**p=0.0009), IL-2-treated mice 
(**p=0.0008) and NK-92-scFv(FRP5)-zeta-treated mice (*p=0.002). There was no statistically significant 
difference in survival of control groups.  
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4. Discussion 
4.1. Immunotherapy in NB 
  Neuroblastoma (NB) is an aggressive childhood malignancy, with about 50% of 
patients exhibiting a high-risk phenotype associated with poor prognosis [2]. Despite 
intensive therapy protocols based on radiation, chemotherapy, stem cell support and 
differentiation therapy, standard treatment fails to successfully control high-risk NB in the 
majority of patients, resulting in the development of progressive disease or relapse. The 
induction of drug resistance in response to intensive therapy is a major obstacle to 
treatment with conventional therapies. Hence, the development and refinement of effective 
alternative therapies are of great importance. In this respect, immunotherapy is 
increasingly attractive. Clinical evidence of the potential of immunotherapy in NB was 
demonstrated in a phase III trial conducted by the Children’s Oncology Group in the US, 
based on a protocol including a combination of the GD2-specific antibody ch14.18, IL-2, 
GM-CSF and 13-cis-retinoic acid [74]. This new treatment approach resulted in a 
significant increase in the two year event-free survival rate from 46 to 66%. Although this 
shows the potential of immunotherapy in NB, it also emphasizes the need for further 
improvement of therapeutic regimens, since about 30% of high-risk patients still do not 
survive the disease.   
  The most advanced immunotherapeutic approaches in NB are based on targeting the 
disialoganglioside GD2. Due to its abundant expression on NB cells but restricted 
physiological expression in the brain and peripheral nerve fibers [29], GD2 is a suitable 
antigen for passive immunotherapy with specific antibodies. With regard to the 
development of evasion mechanisms by the tumor, it is important that GD2 was shown not 
to be modulated off the cell membrane in response to GD2-targeted immunotherapy [31]. A 
combination of antibody-based immunotherapy and adoptive transfer of immune effector 
cells might further increase the therapeutic efficacy of immunotherapeutic approaches 
targeting GD2.  
4.2. Cellular therapy and chimeric antigen receptors 
  According to the missing self hypothesis, low or absent MHC class I expression 
renders NB cells sensitive to NK cell lysis. Therefore, the use of NK cells as immune 
effector cells for adoptive transfer is attractive. In general, cellular therapy with NK cells can 
be based on reinfusion of ex vivo stimulated and expanded autologous NK or lymphokine 
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activated killer cells (LAK cells), or the application of allogeneic cells in particular in a 
haploidentical setting.  
  Clinical responses to a therapeutic application of autologous NK or LAK cells have 
been only moderate [159-161]. The match of MHC class I molecules on tumor cells and 
inhibitory KIR expressed on NK cells is a factor that can negatively affect the efficacy of 
therapy with autologous NK cells. Importantly, due to independent inheritance of KIR and 
HLA class I genes, HLA/KIR mismatch can also happen in the autologous setting. This 
means that a person expresses a certain KIR but simultaneously lacks expression of the 
respective HLA class I molecule, recognized by that KIR. This autologous KIR/HLA 
mismatch has been shown to be beneficial in terms of improved outcome of patients [162]. 
A retrospective study in high-risk NB patients who received an autologous HSCT 
demonstrated that KIR/HLA mismatch is a prognostic factor for an improved outcome of 
patients [163]. Another factor that has to be considered for the application of autologous 
cells is the observation that the functionality of NK cells can be impaired in cancer patients. 
Different mechanisms have been suggested to be involved in this phenomenon 
[summarized in 164]. One is a decreased expression of activating NK cell receptors, such 
as NCRs or NKG2D [95, 165]. Furthermore, decreased expression or impaired function of 
the signal-transducing zeta chain in patient T cells and NK cells has been reported for 
various malignancies, such as cervical cancer, colorectal carcinoma, ovarian carcinoma, 
prostate cancer and myeloid malignancies [166-170]. Additionally, redistribution of NK cell 
subsets in favor of the less cytotoxic CD16dim CD56bright has been reported for cancer 
patients [171, 172]. 
  With regard to these problems, the use of allogeneic cells (particularly haploidentical 
NK cells) is appealing. The mismatch between MHC class I molecules on the patients’ 
tumor cells and inhibitory KIRs on donor NK cells in an allogeneic setting is beneficial to 
activation of NK cells due to the lack of inhibitory signaling [173, 174]. Additionally, NK cells 
expanded from a healthy donor might exhibit improved functionality compared to the 
patient’s NK cells. Clinical applications of allogeneic haploidentical NK cells in particular in 
the setting of hematopoietic stem cell transplantation, have shown more promising results 
[175-180].  
   Independent of the autologous or allogeneic nature of NK cells applied within an 
immunotherapeutic approach, tumor cells can develop escape strategies to evade 
recognition by NK cells. This includes shedding as well as down regulation of activating 
ligands or release of soluble factors (such as TGF-β), eventually resulting in down 
regulation of activating receptors on NK cells or their respective ligands on tumor cells [37-
42, 181]. The application of a chimeric antigen receptor (CAR) in order to specifically direct 
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NK cells to tumor target cells and, at the same time, provide for an activation signal 
following specific targeting of a TAA is an approach to overcome these evasion strategies. 
In the case of NB, the disialoganglioside GD2 is an established target antigen for passive 
immunotherapy based on the application of GD2-specific antibodies. Chimeric antigen 
receptors have been generated to combine antibody-based immunotherapeutic 
approaches and the adoptive transfer of immune effector cells to increase the therapeutic 
potential. In general, CARs are not dependent on presentation of antigens in the context of 
MHC class I molecules and therefore are able to recognize carbohydrate or glycolipid 
antigens in addition to protein antigens. Importantly, the expression of chimeric antigen 
receptors provides effector cells with a certain specificity and thereby overcomes the above 
mentioned immune evasion strategies, since lysis is not only dependent on interaction of 
activating NK cell receptors with their respective ligands on tumor cells anymore.  
  In comparison to the application of anti-GD2 antibodies, the use of CAR-expressing 
effector cells might be especially beneficial for patients who only express Fc receptors for 
IgG (FcγR) with low affinity for the therapeutic antibody. This correlation between the 
affinity of the FcγR and clinical efficacy of antibody-based immunotherapy has been 
reported across a variety of therapeutic antibody applications [182-185]. Interestingly, 
studies indicated that the use of CAR-expressing effector cells might compare favorably to 
the use of a combination of monoclonal antibodies and NK cells [148]. Patients who did not 
respond to therapy with the chimeric bispecific antibody blinatumomab (anti-CD19 and anti-
CD3) were shown to respond to CAR-expressing effector cells [186]. Furthermore, 
immunotherapeutic studies based on the application of the GD2-specific immunocytokine 
hu14.18-IL2 have shown correlations between HLA/KIR mismatch and improved outcome 
[187, 188]. In addition to the potential benefit of a CAR-based approach compared to the 
application of an TAA-specific antibody, this also suggests that the application of a CAR-
expressing allogeneic cell line might be especially beneficial for patients who do not exhibit 
an autologous HLA/KIR mismatch status.  
  Another challenge to passive immunotherapy with monoclonal antibodies is that 
patients are very often heavily pre-treated with high-dose multi-agent chemotherapy. This 
application of cytostatic agents negatively affects numbers and cytotoxic activity of 
endogenous immune cells, resulting in immune suppression of patients. In this respect, the 
adoptive transfer of CAR-engineered allogeneic effector cells is becoming increasingly 
attractive as a substitute for functionally impaired endogenous immune cells, thereby 
suggesting a greater therapeutic potential for immunotherapeutic applications. 
    Cellular therapy based on the adoptive transfer of CAR-expressing effector cells, 
mainly T cells, has already entered clinical trials. So far, approaches using 1st generation 
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CARs have shown only modest success [189-191]. Interestingly, the exception was a 
phase I clinical trial in NB patients treated with autologous T cells that were genetically 
engineered to express a GD2-specific CAR [192]. In detail, 11 patients received a 
combination of CAR-expressing activated T cells (ATC) and CAR-expressing CTLs that are 
specific for Epstein Barr-virus (EBV), intended to provide additional co-stimulation. CAR-
expressing CTLs were detectable at six weeks after injection, while CAR expressing ATC 
were only detectable until three weeks after injection. Four out of eight patients that 
entered the study with detectable disease responded with tumor necrosis or tumor 
regression after treatment with GD2-specific autologous T cells [192]. Long-term 
monitoring of these patients and eight additional patients demonstrated comparable 
persistence of both effector cell populations at a low level for up to four years [146]. 
Persistence of either cell type correlated with prolonged time to disease progression in 11 
patients with active disease. Three out of these 11 patients experienced complete 
response. Importantly, in addition to these responses, this phase one trial demonstrated 
that the therapeutic application of CAR-expressing effector cells was safe and well 
tolerated. According to clinical trials based on the therapeutic application of GD2-specific 
antibodies, neuropathic pain is a major side effect due to physiological expression of GD2 
on peripheral nerve fibers. This side effect was not reported upon treatment with GD2-
CAR-expressing effector cells. So far, studies showed that neuropathic pain is potentially 
caused by recognition of GD2 on peripheral nerve fibers, and subsequent activation of the 
complement system, based on the interaction between complement proteins and the Fc 
part of the anti-GD2 antibody [193]. This suggests that in the case of GD2-targeting 
therapeutic strategies, the use of CAR-expressing effector cells might be beneficial 
compared to the application of GD2-specific antibodies, because the CAR does not contain 
a Fc part and therefore does not activate the complement system. Furthermore, it was 
reported that treatment of patients with GD2-CAR-expressing effector cells did not induce 
the generation of antibodies against the CAR [146]. 
  To address the problem of low persistence and expansion of 1st generation CAR-
expressing effector cells which resulted in only modest therapeutic effects, effector cells 
expressing a 2nd generation CAR including a co-stimulatory domain have been developed 
and entered clinical trials [reviewed in 194-196]. So far, the most promising results 
regarding persistence and expansion of CAR-expressing effector cells and clinical 
response have been demonstrated towards CD19+ hematological malignancies [145, 186, 
197, 198]. Kochenderfer et al. [197] reported results of a clinical application of CD28-CD3ζ 
CAR-T cells specifically targeting CD19. Out of eight patients, five experienced partial 
remission and one patient showed complete remission.  In the majority of patients CAR-T 
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cells were detectable up to 50 days, while in some patients CAR-T cells persisted for 130 
days or longer. Persistence of CD19 specific 4-1BB-CD3ζ CAR-T cells for up to six months 
was reported by Kalos et al. [145] in three patients with chronic lymphocytic leukemia 
(CLL). Importantly, CAR-T cells expanded more than 1000-fold after infusion into patients. 
Two of these patients experienced complete remission, while a third patient showed a 
partial response. Porter et al. [198] reported results of the treatment of one additional CLL 
patient with 4-1BB-CD3ζ CAR-T cells. This patient also experienced complete remission of 
disease and showed greater than 1000-fold expansion of CAR-T cells which persisted for 
six months. These promising results were confirmed by the use of 4-1BB-CD3ζ CAR-T 
cells in two patients with acute lymphoid leukemia (ALL) [186]. Expansion of CAR-T cells 
greater than 1000-fold as well as persistence of cells for six months and longer was 
confirmed in both patients. Treatment with 4-1BB-CD3ζ CAR-T cells resulted in complete 
remission in both patients, with one patient maintaining complete remission after nine 
months. The other patient relapsed two months after treatment.     
  Not many 3rd generation CARs, which include several co-stimulatory domains have 
entered clinical trials so far. A CD20-specific 3rd generation CAR containing CD28 and 4-
1BB co-stimulatory domains was utilized in a pilot clinical trial [147]. Out of four patients 
with follicular lymphoma or mantle cell lymphoma that enrolled to the study, three patients 
received CAR-expressing T cells. Two of these patients entered the study without 
evaluable disease and remained progression-free for 12 and 24 months after treatment. 
The third patient entered partial remission but relapsed 12 months after treatment. 
Importantly, CAR-expression on infused modified T cells was only detectable with PCR and 
persistence of cells in patients was confirmed up 12 months after treatment. In contrast, the 
application of T cells expressing a 3rd generation ErbB2-specific CAR, containing CD28 
and 4-1BB co-stimulatory domains, in a patient with colorectal cancer caused a serious 
adverse event resulting in death [199]. 
  All of the above mentioned CAR-based immunotherapeutic approaches have utilized 
T cells as effector cells. Since the understanding of NK cell biology and regulation of NK 
cell activation is evolving, the use of NK cells as alternative effector cells is becoming 
increasingly attractive. In contrast to T cells, NK cells mediate a non-MHC-restricted natural 
cytotoxicity without any prior sensitization [80, 83]. Importantly, this natural cytotoxicity of 
NK cells has already been shown to play a role in the lysis of NB cells [35, 36, 200]. 
Although T cells are advantageous with regard to initial number of effector cells which can 
be isolated from peripheral blood, progress has been made in the establishment of 
protocols for NK isolation and ex vivo expansion and activation, compensating for the initial 
lower cell count. These improved protocols are based on the expansion of NK cells using 
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an artificial antigen presenting cell line generated by genetic engineering of K562 to 
express one or several activating ligands, such as CD137L or MICA and IL-15 or IL-21 as a 
membrane-bound activating cytokine [201-204]. Within several expansion cycles, NK cell 
numbers can be expanded up to 47,967-fold depending on the artificial antigen presenting 
cell line that is used. These new and improved NK cell expansion and activation protocols 
potentially compensate the initial difference in cell numbers of T cells and NK cells. 
Importantly, NK cells might be advantageous as effector cells compared to T cells in an 
allogeneic adoptive transfer setting. It has been shown that NK cells mediate cytotoxicity in 
the graft versus tumor direction but do not cause graft-versus-host disease (GvHD), a 
serious complication that is potentially mediated by T cells [177, 205, 206]. The shorter life 
span of NK cells compared to T cells might be beneficial with regard to long-term side 
effects which can be potentially mediated by memory-like T cells [207]. Such a long-term 
side effect has been reported in clinical trials based on the application of CD19-specific 
CAR-expressing T cells, which resulted in long-term depletion of normal B cells [197, 198]. 
  Based on these advantages of NK cells, the approach of CAR-based immunotherapy 
has already been expanded to NK cells as effector cells [133, 143, 208]. Although these 
studies demonstrated the feasibility of a CAR-based approach employing NK cells as 
effector cells, they also demonstrated that there are still limitations regarding donor-
dependent extensive variations in transfection efficacy and CAR functionality [133, 143]. 
Furthermore, ex vivo expansion, activation and genetic engineering of autologous or 
allogeneic primary NK cells for each individual patient is time intensive and requires 
substantial resources. 
  The human NK cell line NK-92 is a promising alternative to address the problems 
associated with the use of primary NK cells. In contrast to primary patient-derived NK cells 
that might be functionally impaired, NK-92 provides unrestricted alloreactivity due to lack of 
expression of KIRs [119]. NK-92 has been shown to exhibit a high cytotoxicity against a 
variety of cancer cell lines and primary cancer cells [116-118]. As a prerequisite for a 
clinical application large scale expansion of NK-92 can be easily performed under good 
manufacturing practices (GMP) [121, 122]. NK-92 expressing CARs of various specificities 
have already been generated [140, 142, 148, 209, 210], demonstrating the feasibility of 
genetic engineering of NK-92. Once CAR-expressing NK-92 of certain specificity are 
generated, they can be provided on demand in a standardized quality and can be used not 
only for one specific patient but many different patients. This non-individualized approach is 
advantageous compared to the use of patient-derived effector cells, because it 
compensates for functional impairment of primary effector cells as well as donor- 
dependent variations in ex vivo expansion rates, transfection efficacy and CAR-
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functionality. Most importantly, the characteristic of being ready on demand in a 
standardized quality circumvents the obstacle of time and labor consuming isolation, 
transfection, expansion and testing of patient-derived effector cells. This reduction in lead 
time is an important prerequisite for the initiation of multicenter clinical trials in the 
maintenance therapy immediately after conventional therapy to prevent a relapse. 
  To expand this approach to NB, this thesis aimed to analyze the mechanism and 
efficacy of a cellular therapy based on a human NK cell line expressing a GD2-specific 
CAR (NK-92-scFv(ch14.18)-zeta).   
4.3. Effect and mechanism of a GD2-directed NK CAR therapy 
approach based on NK-92-scFv(ch14.18)-zeta 
  The initial part of this study involved the analysis of CAR-expression on NK-92-
scFv(ch14.18)-zeta as well as the control cell lines NK-92, NK-92-pLXSN, and NK-92-
scFv(FRP5)-zeta with flow cytometry, because CAR-expression is the prerequisite for 
GD2-specific lysis of target cells. High homogenous CAR-expression was confirmed for 
NK-92-scFv(FRP5)-zeta and NK-92-scFv(ch14.18)-zeta, with only NK-92-scFv(ch14.18)-
zeta expressing a GD2-specific CAR (Fig. 3.1.1). In vitro cytotoxicity assays demonstrated 
significantly higher lysis of GD2-expressing NB cell lines mediated by NK-92-
scFv(ch14.18)-zeta compared to control NK cell lines (Fig. 3.1.2-3.2). As the development 
of drug-resistance remains a major challenge in NB treatment with conventional therapies, 
the panel of GD2-positive target cell lines tested in these assays also included NB cell 
lines, which are known to be partially or even multidrug-resistant. This was intended to 
assess the sensitivity of NB cell lines towards a GD2-targeted approach with NK-92-
scFv(ch14.18)-zeta. NK-92-scFv(ch14.18)-zeta effectively lysed all tested NB cell lines, 
even those with a drug-resistant phenotype, indicating that targeting GD2 with a cellular 
approach based on NK-92-scFv(ch14.18)-zeta might offer an alternative therapeutic 
approach to address the problem of acquired drug-resistance with conventional therapies. 
  The role of the interaction between the target antigen GD2 and the CAR for cytotoxic 
activity of NK-92-scFv(ch14.18)-zeta was assessed in additional in vitro cytotoxicity assays 
by disrupting the interaction, either by blocking the CAR with an anti-IdAb (Fig. 3.3.1 and 
3.3.2) or by blocking the target antigen GD2 by addition of the GD2-specific antibody 
ch14.18 (Fig. 3.3.3) during co-incubation of NK-scFv(ch14.18)-zeta and target cells. Both 
strategies resulted in significant abrogation of NK-92-scFv(ch14.18)-zeta-mediated lysis of 
GD2-positive target cells. Importantly, lysis was almost completely abrogated, indicating 
that recognition of GD2 by the CAR is the primary mechanism of activation of NK-92-
scFv(ch14.18)-zeta-mediated lysis. To directly analyze the impact of GD2-expression on 
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NK-92-scFv(ch14.18)-zeta-mediated lysis of NB cell lines, GD2-expression on NB target 
cells was decreased by inhibition of glucosylceramide synthase (GCS) with the selective 
inhibitor PPPP. Inhibition of GCS, and thereby inhibited conversion of ceramides to 
glucosylceramides, abrogates the first step in ganglioside synthesis. Significantly 
decreased GD2-expression on PPPP-treated target cells (Fig. 3.3.6) resulted in significant 
abrogation of target cell lysis mediated by NK-92-scFv(ch14.18)-zeta (Fig. 3.3.7). This 
demonstrates a direct correlation between GD2-expression and NK-92-scFv(ch14.18)-
zeta-mediated lysis. Additionally, the potential for GD2 alone to induce activation of NK-92-
scFv(ch14.18)-zeta in absence of other activating stimuli was analyzed in a target cell-free 
experimental setting, based on immobilized GD2 (Fig. 3.3.4 and 3.3.5). Immobilized GD2 
was sufficient to stimulate a significantly increased release of granzyme B and perforin, 
indicating activation of NK-92-scFv(ch14.18)-zeta. This effect was abrogated by blocking 
the CAR, confirming that activation is mediated by interaction of the CAR with immobilized 
GD2, which demonstrated that immobilized GD2 is sufficient to induce activation of NK-92-
scFv(ch14.18)-zeta. This finding is particularly important, considering the general 
complexity and tight regulation of NK cell activation and that sometimes several activating 
receptors must be synergistically engaged to induce activation and cytotoxicity of NK cells. 
Importantly, these experiments demonstrate that recognition of GD2 by the CAR results in 
activating signaling, leading to the release of effector molecules. This suggests that GD2-
specific lysis of NK-92-scFv(ch14.18)-zeta is actually due to activation of CAR signaling 
and not due to binding of the target cell via the CAR and activation via another 
ligand/receptor interaction. Additionally, these results indicate that targeting GD2 with the 
GD2-specific CAR expressed on NK-92-scFv(ch14.18)-zeta would allow the therapy to 
overcome escape mechanisms developed by cancer cells, such as shedding of activating 
ligands.  
  Based on the establishment of GD2-specificity and functionality of CAR-expressing 
NK-92-scFv(ch14.18)-zeta we could clearly show the primary role of the interaction of GD2 
with the CAR for activation of NK-92scFv(ch14.18)-zeta and thereby NK-92-scFv(ch14.18)-
zeta-mediated lysis. NK-92-scFv(ch14.18)-zeta were then used to address the problem of 
developing effective therapy against refractory relapse cell lines which remains a major 
challenge in high-risk NB treatment with conventional therapies. NB cell line pairs of four 
patients, each consisting of a cell line generated at time of diagnosis and a corresponding 
relapse cell line, were analyzed for their sensitivity towards NK-92-scFv(ch14.18)-zeta (Fig. 
3.4.1). Importantly, all relapse cell lines were sensitive towards NK-92-scfv(ch14.18)-zeta-
mediated lysis with three out of four relapse cell lines displaying even higher sensitivity 
than the corresponding cell line from time of diagnosis. This finding correlated with an 
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increased GD2-expression in the respective relapse cell lines (Fig. 3.4.2). Since it was 
shown that GCS, as the first enzyme in ganglioside synthesis has an impact on GD2 
expression, GCS-expression in all cell line pairs was analyzed with Western blot (Fig. 
3.4.3). This analysis revealed an increase in GCS-expression in three relapse cell lines 
compared to their corresponding cell line from diagnosis. The fourth relapse cell line 
displayed only slightly increased GCS-expression. While this last observation remains of 
interest, it would be necessary to analyze a greater number of cell line pairs to confirm this 
finding. 
  These encouraging in vitro results provided a baseline to test the therapeutic efficacy 
of NK-92-scFv(ch14.18)-zeta in vivo in a drug-resistant xenograft mouse model. This 
mouse model was based on induction of a subcutaneous human NB tumor followed by 
repeated peritumoral applications of NK cells, in combination with IL-2 to promote the 
survival of NK cells as well as to maintain high CAR-expression. Injection of NK cells was 
started on day three after tumor cell inoculation (Fig. 3.5.1). Since the idea of a cellular 
immunotherapy following conventional standard therapy is to treat minimal residual disease 
(MRD), which could otherwise potentially lead to relapse, NK cell injections were started at 
a time point with no palpable or visible signs of a tumor. Monitoring of tumor growth in all 
experimental groups revealed that palpable tumors appeared later in NK-92-
scFv(ch14.18)-zeta-treated mice, and tumor growth rates were significantly delayed. 
Control groups displayed aggressive tumor growth, in contrast to NK-92-scFv(ch14.18)-
zeta-treated mice, in which NK cell injections suppressed tumor growth in the majority of 
treated mice (Fig. 3.5.3 and 3.5.4). Mice in this NK-92-scFv(ch14.18)-zeta-treated group 
developed tumors after the end of NK cell treatment. Interestingly, tumors of mice receiving 
NK-92-scFv(ch14.18)-zeta already showed signs of necrosis at smaller tumor volumes 
than control groups and therefore had to be sacrificed before the maximal tumor volume 
was reached. These data provide a proof of concept that therapeutic application of NK-92-
scFv(ch14.18)-zeta can mediate an in vivo anti-tumor effect towards an aggressively 
growing tumor and leads to significantly prolonged survival in mice receiving GD2-specific 
therapy (Fig. 3.5.5).    
4.4. Toxicities and potential side effects of CAR-based approaches 
and strategies for circumvention  
  Despite its potential for cancer therapy, the use of genetically modified effector cells 
expressing a CAR can be accompanied by potential toxicities and side effects. On-target 
toxicities on healthy tissue are one major complication that should be considered. These 
toxicities most likely occur if healthy tissue also displays expression of the target antigen, 
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resulting in the destruction of healthy cells. Hence, target antigens for CAR-based 
immunotherapeutic approaches should be carefully chosen with high levels of expression 
on the tumor but restricted physiological expression. However, the desired on-target 
toxicity towards the tumor can also be accompanied by severe side effects. Strong 
activation of CAR-expressing effector cells, or activation of a high number of effector cells 
at the same time and subsequent destruction of tumor cells, may result in the release of 
high amounts of cytokines, such as TNF-α, IFN-γ, IL-2 or IL-6, leading to cytokine release 
syndrome (CRS). This can cause severe fever or hypotension and might result in life-
threatening conditions, including multiple organ dysfunction [211-213]. Clinical applications 
of CAR-expressing T cells have reported the development of CRS as a side effect of 
adoptive transfer of CAR-expressing effector cells [197, 199]. 
   Avoiding these toxicities and potential side effects is a major challenge for the 
therapeutic application of CAR-expressing effector cells. To address this problem of on-
target toxicities towards healthy tissue, a new CAR approach is currently under 
investigation, based on the co-expression of an antigen-specific CAR and a chimeric co-
stimulatory receptor (CCR) [214]. In this approach, an antigen-specific CAR that mediates 
only suboptimal activation is combined with a second receptor recognizing another antigen 
on the tumor and providing co-stimulation. Hence, effector cells only receive enough 
activation when both the CAR and the CCR interact with their respective antigen on the 
tumor. Engagement of only one of two receptors with their respective ligand provides only 
insufficient stimulation of effector cells. This potentially avoids toxicity towards healthy 
tissue when antigens are used that are not absolutely restricted to the tumor but are also 
expressed to some extent on healthy tissue [214]. Alternatively, the feasibility of a 
combination of an activating CAR recognizing a TAA and a second inhibitory CAR, 
specifically recognizing an antigen that is expressed on normal tissue, is under 
investigation to address the problem of on target, off organ toxicities [215]. In this 
approach, inhibitory CARs (iCARs) are based on the expression of inhibitory intracellular 
signaling domains of the immunoinhibitory receptors CTLA-4 and PD-1. Co-expression of 
activating CAR and iCAR was reported to result in inhibition of on-target cytotoxicity 
against other organs than the tumor when the iCAR encounters its respective antigen 
expressed on normal tissue [215].    
  Regarding the development of CRS, several aspects have to be considered. Since 
the extend of CRS has been shown to correlate with the disease burden [213, 216], the risk 
of CRS might be reduced by the restriction of CAR-based immunotherapy to a minimal 
residual disease setting. Further, the CAR-design might have an impact on potential side 
effects. Although improvement of CAR design based on the addition of co-stimulatory 
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domains might be beneficial in terms of stronger activation, prolonged persistence or 
increased proliferation of engineered effector cells, this might also require investigation into 
possible side effects related to strong activation or proliferation of TAA-specific effector 
cells. Even if the use of autologous effector cells might be beneficial in terms of low 
immunogenicity of CAR-expressing effector cells and therefore persistence of these cells, 
there is also the potential disadvantage of extensive proliferation of effector cells in 
response to TAA recognition on the tumor. This might result in increased numbers of 
effector cells reaching a threshold at which activation of these effector cells could 
potentially cause a CRS. To address this potential safety concern, suicide switches have 
been incorporated into the concept of adoptive transfer of CAR-expressing effector cells 
[217]. Safety switches based on the Herpes simplex virus thymidine kinase [218], inducible 
caspase 9 [219] and CD20 [220] have already been generated. These suicide switches 
enable elimination of CAR-expressing effector cells in the case of critical proliferation. The 
disadvantage of this approach would be that the effect is not some kind of preventive 
therapy and will be used when indications for too high effector cell numbers or 
pathologically elevated high cytokine levels are already detectable. Additionally, suicide 
gene-based induction of apoptosis would also completely abrogate the therapeutic effect of 
CAR-expressing cells.  
  Alternatively, the use of non-proliferating effector cells or effector cells which exhibit 
only transient CAR-expression, facilitated by transfection with mRNA encoding for the 
CAR, might be disadvantageous in terms of persistence of the anti-tumor effect but might 
be beneficial with regard to the safety of the therapeutic approach [137, 221, 222]. 
Irradiation can prevent proliferation of effector cells while maintaining cytotoxic activity. The 
advantage of non-proliferating effector cells is that the procedure of their therapeutic 
application would be comparable to the application of conventional therapeutic agents. 
Since the effector cells do not proliferate, the exact dosage can be calculated and dose 
escalation can be performed to determine a maximal tolerated dose that is not associated 
with severe side effects. Further, in case of unexpected adverse events, treatment can 
immediately be stopped by discontinuing the injection of cells or by halting additional 
effector cell injections. Therefore, the application of non-proliferating cells appears to be 
safer and more predictable. On the other hand, this approach may potentially require 
injection of higher cell numbers and repeated application of effector cells to maintain an 
anti-tumor response. Generation of sufficient numbers of CAR-expressing effector cells is 
therefore a crucial prerequisite. Due to recent improvements of protocols for NK cell 
isolation and ex vivo expansion [201-204], NK cells are an increasingly attractive effector 
cell population for CAR-based immunotherapeutic approaches. NK cells appear to be 
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advantageous with regard to their natural cytotoxicity especially towards tumor entities that 
lack MHC class I but still express activating NK cell ligands. NK cells also have an 
improved safety profile in an allogeneic setting, since they exhibit an increased cytotoxicity 
compared to the autologous setting but do not cause GvHD, a potential severe 
complication that can be caused by allogeneic T cells [177, 205, 206].  
  Unless endogenous T cell receptor genes are removed during genetic engineering, T 
cells still express their T cell receptor in addition to the TAA-specific CAR. When those T 
cells encounter their respective TAA recognized by the CAR, they get activated and 
proliferate. Expansion of this T cell population does not only mean expansion of TAA-
specific CAR-expressing T cells, but also proliferation of T cells with a T cell receptor of 
unknown specificity, which might be another safety concern. Additionally, memory-like 
features of T cells compared to NK cells might be beneficial with regard to retaining a long-
term anti-tumor response, but also bear the potential risk of long-term side effects if the 
TAA is not exclusively expressed on tumor tissue only [197, 198, 207].  
  Another aspect to be considered is the potential immunogenicity of the expressed 
CAR as a “foreign” protein. In the case of CAR-generation based on scFvs consisting of 
murine variable regions, there is the possibility that this might induce an immune response 
directed against the CAR, resulting in clearance of CAR-expressing effector cells from the 
system and thereby abrogation of the therapeutic activity. The development of anti-idiotype 
antibodies specifically binding the paratopes of the CAR has been reported in a number of 
cases [190, 223, 224], in contrast to others not showing the induction of anti-idiotype 
antibodies [189]. The use of scFvs that were derived from humanized antibodies for CAR 
generation might be beneficial in terms of lower potential to induce anti-idiotype antibodies. 
Interestingly, in the clinical application of murine GD2-specific antibodies, the induction of 
human anti-mouse antibodies (HAMA) correlated with improved outcome of patients [59]. 
This might be due to the induction of anti-anti-idiotype antibodies according to the anti-
idiotype network theory [60], which recognize the nominal antigen GD2. In addition to these 
humoral immune responses, genetically engineered effector cells can also induce cell-
mediated immune responses, which potentially limit therapeutic efficacy [223, 225].    
   The therapeutic approach presented in this study is based on the repeated 
application of a human NK cell line expressing a GD2-specific CAR (NK-92-scFv(ch14.18)-
zeta). With regard to a clinical application, NK-92-scFv(ch14.18)-zeta can be irradiated to 
prevent proliferation. Parental NK-92 cells tested in clinical trials have been subjected to 
irradiation with 10 Gy prior to injection [124, 125], and the cytotoxicity of irradiated GD2-
specific NK-92-scFv(ch14.18)-zeta has been shown to be comparable to non-irradiated 
NK-92-scFv(ch14.18)-zeta [150]. This is a prerequisite for the safety of the injection of a 
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human NK cell line into patients to avoid induction of a lymphoproliferative disease. 
Importantly, these cells can be expanded under GMP conditions to provide sufficient cell 
numbers for repeated injections during therapy, another prerequisite for a clinical 
application. So far, two clinical trials investigated the application of parental NK-92 cells in 
patients with advanced malignancies. The first phase I study analyzed the safety of NK-92 
administration in 12 patients with renal cancer or melanoma based on a dose escalation 
including four different dose levels 1x108/m2, 3x108/m2, 1x109/m2 and 3x109/m2 [124]. 
Patients received three infusions of the respective NK-92 cell number within a 48 h infusion 
period on days 1, 3 and 5. NK-92 application was well tolerated, mainly accompanied only 
by grade 1 fever as well as grade 3 and grade 4 hypoglycemia observed in two patients 
only. The second phase I study was based on treatment of 15 patients with solid 
tumors/sarcomas or leukemia/lymphoma [125]. Patients were subjected to two NK-92 
injections, 48 h apart from each other with a dose escalation including three different NK-
92 dose levels (1x109/m2, 3x109/m2, 1x1010/m2). One patient received additional NK-92 
infusions (5 infusions over a 6 month period). Importantly, NK-92 infusions were well 
tolerated, and analysis of persistence of NK-92 cells in two patients demonstrated that NK-
92 was detectable in the circulation up to 48 hours after injection.  
  Addressing the problem of allogenicity of this cell line, and thereby potential immune 
reactions of the patient’s immune system towards these cells, patients were selected for 
the clinical trial based on the absence of cross-match with NK-92. The first study revealed 
anti-HLA antibodies recognizing NK-92 in one out of two patients tested [124]. However, in 
the second study only one out of seven patients was tested positive for anti-HLA antibodies 
1 and 4 weeks after NK-92 application. Although both studies aimed at investigating the 
safety of repeated NK-92 infusions, some responses have been seen in both studies [125]. 
The first study reported a minor response in a patient with metastatic melanoma and a 
mixed response in a patient with renal cell carcinoma [124]. In the second study, two 
patients with advanced lung cancer showed clinically significant mixed responses, and 
treatment of another patient with lung cancer resulted in stable disease for about two years 
[125]. These data demonstrated that repeated application of NK-92 is safe and well 
tolerated with evidence for clinical activity in patients with advanced cancer. Importantly, 
immune reactions towards NK-92 were rare, suggesting that a repeated application of NK-
92 is feasible for treatment of advanced cancer. These data regarding the parental NK-92 
cell line suggest that an application of the GD2-specific cell line NK-92-scFv(ch14.18)-zeta 
will have a similar safety and activity profile. Based on these considerations, the findings 
reported here provide an important baseline for the design of phase I/II clinical trials to 
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address tolerability of and response to NK-92-scFv(ch14.18)-zeta therapy in a highly 
challenging population of stage 4 NB patients.  
4.5. Conclusion  
  In vitro as well as in vivo data generated within the present study provide definite 
evidence for specificity of NK-92-scFv(ch14.18)-zeta and efficacy of a GD2-targeted 
cellular approach against drug-resistant NB. Importantly, the interaction of the target 
antigen GD2 on tumor cells with the CAR was shown to be the primary mechanism of 
activation and subsequent tumor cell lysis mediated by NK-92-scFv(ch14.18)-zeta. The use 
of allogeneic GD2-specific NK-92-scFv(ch14.18)-zeta might further increase the 
therapeutic potential of an anti-GD2 immunotherapy. As a non-individualized cellular 
therapy, the use of NK-92-scFv(ch14.18)-zeta is independent from primary patient cells. 
Therefore, the present therapy could remain a therapeutic option for heavily pre-treated 
patients with poorly functioning primary immune cells or unfavorable conditions regarding 
FcγR affinity or HLA/KIR mismatch status. Importantly, this CAR-based cellular approach is 
likely to have an improved pain toxicity profile compared to GD2-specific antibodies, 
because CARs do not activate the complement system which is responsible for the pain 
side effects. One major benefit of the NK-92-scFv(ch14.18)-zeta cellular approach is that 
effector cells can be made available on demand, which is an important prerequisite to start 
this cell-based maintenance therapy subsequent to conventional therapy in a multicenter 
setting. 
  In conclusion, these considerations and the pre-clinical data generated in the present 
study provide an important rationale for the clinical investigation of tolerability and efficacy 
of NK-92-scFv(ch14.18)-zeta in phase I/II trials to further improve the outcome for highly 
challenging stage 4 NB patients. 
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5. Summary 
  Neuroblastoma (NB) is a solid extracranial childhood malignancy of neuroectodermal 
origin. About 50% of NB patients belong to the high-risk group characterized by poor 
prognosis. Standard multi-modal therapy is based on high dose chemotherapy and stem 
cell support followed by differentiation therapy with 13-cis-retinoic acid. Although this has 
improved the outcome of NB patients, treatment of high-risk NB remains challenging due to 
development of drug-resistant progressive disease or relapse that no longer responds to 
conventional therapy. This emphasizes the urgent need of alternative adjuvant therapy 
regimen. 
  Along this line, the potential of passive immunotherapy for NB treatment has recently 
been shown in a phase III clinical trial. Treatment of high-risk NB patients with a 
combination of a GD2-specific chimeric antibody (ch14.18), IL-2, GM-CSF and 13-cis-
retinoic acid resulted in an increase in the two year event-free survival rate by 20%. 
Despite these promising results, about 30% of the patients still do not survive the disease, 
emphasizing the need for further optimization.  
  The Disialoganglioside GD2 is an established antigen for immunotherapy of NB, due 
to its high expression on almost all NB but restricted physiological expression in the brain 
and peripheral nerve fibers. Cellular therapy of NB with natural killer (NK) cells is especially 
appealing because MHC class I expression is absent or low in most NB, rendering this 
tumor sensitive to NK cell recognition according to the missing self hypothesis. Additionally, 
natural cytotoxicity of NK cells, mediated by interaction of activating receptors expressed 
on NK cells and their respective ligands on tumor cells, has been shown to play a role in 
lysis of NB cells. It is therefore tempting to assume that a combination of passive 
immunotherapy with GD2-specific antibodies and adoptive transfer of NK effector cells 
would result in an improved NB therapy. To achieve this goal an NK cell line expressing a 
GD2-specific chimeric antigen receptor was engineered: NK-92-scFv(ch14.18)-zeta. This 
chimeric antigen receptor (CAR) consists of a GD2-specific scFv-fragment, which was 
generated from ch14.18, and the CD3ζ-chain as intracellular signal-transducing domain.  
  Within this thesis, GD2-specificity of NK-92-scFv(ch14.18)-zeta as well as efficacy 
towards GD2-expressing NB cell lines, including relapse cell lines that exhibit partial or 
multidrug resistance were demonstrated. In vitro experiments utilizing an anti-idiotype 
antibody or a GD2-specific antibody blocking the CAR or the target antigen GD2, 
respectively, resulted in almost complete abrogation of NK-92-scFv(ch14.18)-zeta-
mediated lysis of GD2+ NB cell lines. This indicates that the interaction between the CAR 
and its target GD2 is the main mechanism of activation of NK-92-scFv(ch14.18)-zeta. This 
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finding was confirmed by additional experiments demonstrating that immobilized GD2 is 
sufficient to induce activation of NK-92-scFv(ch14.18)-zeta in the absence of other 
activating stimuli, and that experimental down-regulation of GD2 surface expression 
significantly decreased NK-92-scFv(ch14.18)-zeta-mediated lysis of GD2+ NB cell lines.  
  Importantly, repeated application of NK-92-scFv(ch14.18)-zeta in combination with IL-
2 significantly decreased tumor growth and prolonged survival of mice in an aggressively 
growing drug-resistant xenograft NB mouse model. This provides an important baseline for 
further optimization of this approach with respect to a clinical application. Supporting this 
strategy is the fact that the parental NK-92 cell line can be expanded under GMP 
conditions and has been demonstrated to be safe and well tolerated by patients in clinical 
trials. These findings and the results presented in the current study suggest that GD2-
specific NK-92 has potential for a future clinical application as NB-specific effector cells that 
would be ready on demand in a standardized quality.   
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6. Zusammenfassung 
  Das Neuroblastom (NB) ist ein solider, extrakranieller Tumor neuroektodermalen 
Ursprungs, der sich im Kleinkindalter manifestiert. Etwa 50% aller Patienten gehören der 
Hochrisikogruppe an, welche mit einer schlechten Prognose assoziiert ist. Die multimodale 
Standardtherapie beinhaltet eine Hochdosischemotherapie mit anschließender 
Stammzelltransplantation und einer darauffolgenden Erhaltungstherapie mit 13-cis-
Retinsäure. Die Behandlung der Hochrisikopatienten stellt hierbei eine besondere 
Herausforderung dar, da die Mehrheit zwar auf die initiale Standardtherapie anspricht, im 
weiteren Verlauf jedoch häufig eine fortschreitende Erkrankung oder ein Rezidiv entwickelt, 
welches oftmals Resistenzen gegenüber Chemotherapeutika aufweist.  
  Dies erfordert die Entwicklung neuer Alternativen zur Standardtherapie. Durch eine 
passive Immuntherapie, die sich gegen das NB-assoziierte Disialogangliosid GD2 richtet, 
konnte kürzlich die 2-Jahres-Ereignis-freie Überlebensrate von 46% auf 66% angehoben 
werden. Das Therapieprotokoll basierte dabei auf der kombinierten Gabe des GD2-
spezifischen chimären Antikörpers ch14.18 mit IL-2, GM-CSF und 13-cis Retinsäure. Das 
Disialogangliosid GD2 ist bei dieser Erkrankung ein für die Immuntherapie bereits 
etabliertes NB-assoziiertes Antigen, das eine starke Expression auf nahezu 100% der NB-
Tumoren aufweist, während sich die physiologische Expression auf das Gehirn und 
periphere Nervenbahnen beschränkt. 
  Verschiedene andere Ansätze, basierend auf der Induktion einer zellulären 
Immunität, werden verfolgt, jedoch zeichnen sich NB-Tumore häufig durch eine geringe 
oder fehlende Expression von MHC Klasse I Molekülen aus. Dies wiederum macht eine auf 
NK-Zellen basierende Therapie zu einem ebenfalls vielversprechenden Ansatz zur 
Behandlung dieser aggressiven Erkrankung. Dafür spricht die Tatsache, dass die Lyse von 
NB-Zellen durch verschiedene Mechanismen der natürlichen Zytotoxizität von NK-Zellen 
vermittelt werden kann.  
  Auf Grundlage dieser Erkenntnisse wurde eine NK-Zelllinie generiert, die einen GD2-
spezifischen chimären Antigenrezeptor (chimeric antigen receptor CAR) exprimiert (NK-92-
scFv(ch14.18)-zeta). Die Hauptbestandteile dieses CAR sind ein Einzelkettenantikörper, 
welcher die variablen Regionen des GD2-spezifischen Antikörpers ch14.18 enthält und die 
CD3ζ-Kette als signaltransduzierende Komponente. Die zelluläre Therapie mit NK-92-
scFv(ch14.18)-zeta stellt damit eine Kombination der passiven GD2-gerichteten 
Immuntherapie und des adoptiven Transfers von NK-Zellen dar.  
  Im Rahmen der vorliegenden Arbeit konnte gezeigt werden, dass NK-92-
scFv(ch14.18)-zeta in der Lage sind, auch Chemotherapie-resistente GD2-positive NB-
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Zelllinien effektiv abzutöten. In vitro wurde nachgewiesen, dass eine Unterbrechung der 
Interaktion zwischen dem CAR und GD2, die sowohl durch die Blockierung des CAR als 
auch durch Blockierung von GD2 hervorgerufen werden kann, zur fast vollständigen 
Aufhebung der NK-92-scFv(ch14.18)-zeta-vermittelten Lyse GD2-exprimierender NB-
Zelllinien führt. Dies zeigt, dass die Erkennung und Bindung von GD2 durch den CAR der 
Hauptmechanismus der NK-92-scFv(ch14.18)-zeta-vermittelten Lyse ist. Weiterhin konnte 
demonstriert werden, dass immobilisiertes GD2 als Stimulus für die Aktivierung von NK-92-
scFv(ch14.18)-zeta ausreichend ist und dass eine experimentell induzierte Verringerung 
der GD2-Expression zu einer verminderten Lyse der Zielzellen führt. Die Analyse von NB-
Zelllinienpaaren hat außerdem ergeben, dass auch Zelllinien, die aus Rezidivtumoren 
generiert wurden, sensitiv gegenüber einer NK-92-scFv(ch14.18)-zeta-vermittelten Lyse 
sind und zum Teil sogar eine höhere Sensitivität aufweisen als entsprechende Zelllinien, 
welche zum Diagnosezeitpunkt aus dem gleichen Patienten entwickelt wurden.  
  Abschließend wurde die Effektivität von NK-92-scFv(ch14.18)-zeta darüber hinaus in 
vivo in einem Chemotherapie-resistenten GD2+ Xenograft-Mausmodell gezeigt. Die 
wiederholte therapeutische Applikation von NK-92-scFv(ch14.18)-zeta in Kombination mit 
IL-2 resultierte dabei in einem signifikant verlangsamten Tumorwachstum und einem 
verbesserten Überleben im Vergleich zu den Kontrollgruppen.  
  Die Ergebnisse dieser Arbeit belegen, dass GD2-spezifische NK-92 das Potential für 
eine zukünftige klinische Anwendung besitzen. Bezüglich der Umsetzbarkeit einer solchen 
zellulären Therapie konnten klinische Studien zum adoptiven Transfer der parentalen 
Zelllinie NK-92 bereits zeigen, dass NK-92 in ausreichender Menge unter GMP-
Bedingungen expandiert werden können und dass die Infusion der Zellen sicher und gut 
verträglich ist. Demnach stellt der Einsatz einer solchen GD2-spezifischen NK-Zelllinie, die 
zu jeder Zeit in einer standardisierten Qualität verfügbar wäre, eine vielversprechende 
Alternative zur Behandlung von Hochrisikopatienten dar, deren Erkrankung nicht mehr auf 
die Standardtherapie anspricht. 
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